



(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
30 May 2003 (30.05.2003)

PCT

(10) International Publication Number
WO 03/043636 A1

- (51) International Patent Classification⁷: **A61K 31/4439**, (74) Agent: **POPPE, Regina**; 124 Grenzacherstrasse, CH-4070 Basel (CH).
C07D 417/12, 417/14
- (21) International Application Number: **PCT/EP02/12562** (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.
- (22) International Filing Date:
11 November 2002 (11.11.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
01127312.5 19 November 2001 (19.11.2001) EP
- (71) Applicant: **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, CH-4070 Basel (CH).
- (72) Inventors: **FLOHR, Alexander**; 142 St. Galler-Ring, CH-4054 Basel (CH). **JAKOB-ROETNE, Roland**; Oberer Baselblick 37, 79595 Inzlingen (DE). **NOR-CROSS, Roger, David**; 20 Alte Saline, CH-4310 Rheinfelden (CH). **RIEMER, Claus**; Optizstrasse 5, 79110 Freiburg (DE).
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.


(54) Title: NICOTIN-OR ISONICOTIN BENZOTHAZOLE DERIVATIVES



(57) Abstract: The present invention relates to compounds of the general formula(I) wherein R¹ is phenyl, piperidin-1-yl or morpholinyl; A is-O-and R is-(CH₂)_n-N(R'')-C(O)-lower alkyl, -(CH₂)_n-O-lower alkyl, -(CH₂)_n-O-(CH₂)_n-O-lower alkyl, lower alkyl, -(CH₂)_n-morpholinyl, -(CH₂)_n-phenyl, -(CH₂)_n-N(R'')₂, (CH₂)_n-pyridinyl, -(CH₂)_n-CF₃, (CH₂)_n-2-oxo-pyrrolidinyl or C₄₋₆-cycloalkyl; R'' is independently from each other hydrogen or lower alkyl and n is 1 or 2; or A is-N(R'')-and R is lower alkyl, C₄₋₆-cycloalkyl, -(CH₂)_n-O-lower alkyl, -(CH₂)_n-pyridinyl, -(CH₂)_n-piperidinyl, -(CH₂)_n-phenyl, (CH₂)_n-N(R'')-C(O)-lower alkyl, -(CH₂)_n-morpholinyl, or (CH₂)_n-N(R'')₂; R' and R'' are independently from each other hydrogen or lower alkyl and n is 1 or 2; or A is CH₂ and R is-N(R'')-(CH₂)_m-O-lower alkyl, -N(R'')₂ S-lower alkyl, or is acetidinyl, pyrrolidinyl or piperidinyl, which optionally substituted by hydroxy or lower alkoxy or is morpholinyl, -N(R'')-(CH₂)_m-C₄₋₆-cycloalkyl, -N(R'')-(CH₂)_m-C(O)O-lower alkyl, -N(R'')-(CH₂)_m-C(O)OH, -2-oxo pyrrolidinyl, -N(R'')-C(O)O-lower alkyl, -O(CH₂)_m-O-lower alkyl or alkoxy; R'' is independently from each other hydrogen or lower alkyl and m is 1, 2 or 3; A is S- and R is lower alkyl; or A-R are together piperazinyl, substituted by lower alkyl, -C(O)-lower alkyl or an oxo group, or is piperidinyl, substituted by lower alkoxy or hydroxy, or is morpholinyl, substituted by lower alkyl, or is C₄₋₆-cycloalkyl, -azetidin-1-yl, optionally substituted by hydroxy or lower alkoxy, thiomorpholine-1,1-dioxo, -tetrahydropyran or 2-oxa-5-aza-bicyclo[2.2.1]hept-5-yl; and to pharmaceutically acceptable acid addition salts thereof. It has been found that the compounds of general formula I are adenosine receptor ligands. Specifically, the compounds of the present invention have a good affinity to the A_{2A}-receptor and they are therefore useful in the treatment of diseases related to this receptor.

Nicotin- or isonicotin benzothiazole derivatives

The present invention relates to compounds of the general formula



wherein

R^1 is phenyl, piperidin-1-yl or morpholinyl;

5 A is -O- and

R is $-(CH_2)_n-N(R'')$ -C(O)-lower alkyl, $-(CH_2)_n-O$ -lower alkyl,
 $-(CH_2)_n-O-(CH_2)_n-O$ -lower alkyl, lower alkyl, $-(CH_2)_n$ -morpholinyl,
 $-(CH_2)_n$ -phenyl, $-(CH_2)_n-N(R'')$, $-(CH_2)_n$ -pyridinyl, $-(CH_2)_n-CF_3$,
 $-(CH_2)_n$ -2-oxo-pyrrolidinyl or C_{4-6} -cycloalkyl;

10 R'' is independently from each other hydrogen or lower alkyl and
 n is 1 or 2; or

A is $-N(R')$ - and

R is lower alkyl, C_{4-6} -cycloalkyl, $-(CH_2)_n-O$ -lower alkyl, $-(CH_2)_n$ -pyridinyl,
 $-(CH_2)_n$ -piperidinyl, $-(CH_2)_n$ -phenyl, $-(CH_2)_n-N(R'')$ -C(O)-lower alkyl,
 15 $-(CH_2)_n$ -morpholinyl, or $-(CH_2)_n-N(R'')$;

R' and R'' are independently from each other hydrogen or lower alkyl and
 n is 1 or 2; or

A is $-CH_2$ - and

20 R is $-N(R'')$ - $(CH_2)_m-O$ -lower alkyl, $-N(R'')$, S-lower alkyl, or is acetidinyl,
 pyrrolidinyl or piperidinyl, which are optionally substituted by hydroxy or lower
 alkoxy or is morpholinyl, $-N(R'')$ - $(CH_2)_m-C_{4-6}$ -cycloalkyl,
 $-N(R'')$ - $(CH_2)_m-C(O)O$ -lower alkyl, $-N(R'')$ - $(CH_2)_m-C(O)OH$,
 -2 -oxo-pyrrolidinyl, $-N(R'')$ -C(O)O-lower alkyl, $-O(CH_2)_m-O$ -lower alkyl or alkoxy;

R'' is independently from each other hydrogen or lower alkyl and m is 1, 2 or 3;

or

A is -S- and

5 R is lower alkyl;

or

A-R are together

-piperazinyl, substituted by lower alkyl, -C(O)-lower alkyl or an oxo group, or is piperidinyl, substituted by lower alkoxy or hydroxy, or is morpholinyl, substituted
10 by lower alkyl, or is -C₄₋₆-cycloalkyl, -azetidin-1-yl, optionally substituted by hydroxy or lower alkoxy, thiomorpholine-1,1-dioxo, -tetrahydropyran or 2-oxa-5-aza-bicyclo[2.2.1]hept-5-yl;

and to pharmaceutically acceptable acid addition salts thereof.

It has surprisingly been found that the compounds of general formula I are
15 adenosine receptor ligands. Specifically, the compounds of the present invention have a good affinity to the A_{2A}-receptor and a high selectivity to the A₁- and A₃ receptors.

Adenosine modulates a wide range of physiological functions by interacting with specific cell surface receptors. The potential of adenosine receptors as drug targets was first reviewed in 1982. Adenosine is related both structurally and metabolically to the bioactive
20 nucleotides adenosine triphosphate (ATP), adenosine diphosphate (ADP), adenosine monophosphate (AMP) and cyclic adenosine monophosphate (cAMP); to the biochemical methylating agent S-adenosyl-L-methione (SAM); and structurally to the coenzymes NAD, FAD and coenzyme A; and to RNA. Together adenosine and these related compounds are important in the regulation of many aspects of cellular metabolism and in the modulation
25 of different central nervous system activities.

The receptors for adenosine have been classified as A₁, A_{2A}, A_{2B} and A₃ receptors, belonging to the family of G protein-coupled receptors. Activation of adenosine receptors by adenosine initiates signal transduction mechanism. These mechanisms are dependent on the receptor associated G protein. Each of the adenosine receptor subtypes has been
30 classically characterised by the adenylate cyclase effector system, which utilises cAMP as a second messenger. The A₁ and A₃ receptors, coupled with G_i proteins inhibit adenylate cyclase, leading to a decrease in cellular cAMP levels, while A_{2A} and A_{2B} receptors couple to

G_s proteins and activate adenylate cyclase, leading to an increase in cellular cAMP levels. It is known that the A₁ receptor system include the activation of phospholipase C and modulation of both potassium and calcium ion channels. The A₃ subtype, in addition to its association with adenylate cyclase, also stimulates phospholipase C and so activates
5 calcium ion channels.

The A₁ receptor (326-328 amino acids) was cloned from various species (canine, human, rat, dog, chick, bovine, guinea-pig) with 90-95% sequence identify among the mammalian species. The A_{2A} receptor (409-412 amino acids) was cloned from canine, rat, human, guinea pig and mouse. The A_{2B} receptor (332 amino acids) was cloned from
10 human and mouse with 45% homology of human A_{2B} with human A₁ and A_{2A} receptors. The A₃ receptor (317-320 amino acids) was cloned from human, rat, dog, rabbit and sheep.

The A₁ and A_{2A} receptor subtypes are proposed to play complementary roles in adenosine's regulation of the energy supply. Adenosine, which is a metabolic product of ATP, diffuses from the cell and acts locally to activate adenosine receptors to decrease the
15 oxygen demand (A₁) or increase the oxygen supply (A_{2A}) and so reinstate the balance of energy supply: demand within the tissue. The actions of both subtypes is to increase the amount of available oxygen to tissue and to protect cells against damage caused by a short term imbalance of oxygen. One of the important functions of endogenous adenosine is preventing damage during traumas such as hypoxia, ischaemia, hypotension and seizure
20 activity.

Furthermore, it is known that the binding of the adenosine receptor agonist to mast cells expressing the rat A₃ receptor resulted in increased inositol triphosphate and intracellular calcium concentrations, which potentiated antigen induced secretion of inflammatory mediators. Therefore, the A₃ receptor plays a role in mediating asthmatic
25 attacks and other allergic responses.

Adenosine is a neuromodulator, able to modulate many aspects of physiological brain function. Endogenous adenosine, a central link between energy metabolism and neuronal activity, varies according to behavioural state and (patho)physiological conditions. Under conditions of increased demand and decreased availability of energy
30 (such as hypoxia, hypoglycemia, and/or excessive neuronal activity), adenosine provides a powerful protective feedback mechanism. Interacting with adenosine receptors represents a promising target for therapeutic intervention in a number of neurological and psychiatric diseases such as epilepsy, sleep, movement disorders (Parkinson or Huntington's disease), Alzheimer's disease, depression, schizophrenia, or addiction. An increase in
35 neurotransmitter release follows traumas such as hypoxia, ischaemia and seizures. These neurotransmitters are ultimately responsible for neural degeneration and neural death,

which causes brain damage or death of the individual. The adenosine A_1 agonists which mimic the central inhibitory effects of adenosine may therefore be useful as neuroprotective agents. Adenosine has been proposed as an endogenous anticonvulsant agent, inhibiting glutamate release from excitory neurons and inhibiting neuronal firing.

5 Adenosine agonists therefore may be used as antiepileptic agents. Adenosine antagonists stimulate the activity of the CNS and have proven to be effective as cognition enhancers. Selective A_{2a} antagonists have therapeutic potential in the treatment of various forms of dementia, for example in Alzheimer's disease, and of neurodegenerative disorders, e.g. stroke. Adenosine A_{2a} receptor antagonists modulate the activity of striatal GABAergic

10 neurons and regulate smooth and well-coordinated movements, thus offering a potential therapy for Parkinsonian symptoms. Adenosine is also implicated in a number of physiological processes involved in sedation, hypnosis, schizophrenia, anxiety, pain, respiration, depression, and drug addiction (amphetamine, cocaine, opioids, ethanol, nicotine, cannabinoids). Drugs acting at adenosine receptors therefore have therapeutic

15 potential as sedatives, muscle relaxants, antipsychotics, anxiolytics, analgesics, respiratory stimulants, antidepressants, and to treat drug abuse. They may also be used in the treatment of ADHD (attention deficit hyper-activity disorder).

An important role for adenosine in the cardiovascular system is as a cardioprotective agent. Levels of endogenous adenosine increase in response to ischaemia and hypoxia, and

20 protect cardiac tissue during and after trauma (preconditioning). By acting at the A_1 receptor, adenosine A_1 agonists may protect against the injury caused by myocardial ischemia and reperfusion. The modulating influence of A_{2a} receptors on adrenergic function may have implications for a variety of disorders such as coronary artery disease and heart failure. A_{2a} antagonists may be of therapeutic benefit in situations in which an

25 enhanced antiadrenergic response is desirable, such as during acute myocardial ischemia. Selective antagonists at A_{2a} receptors may also enhance the effectiveness of adenosine in terminating supraventricular arrhythmias.

Adenosine modulates many aspects of renal function, including renin release, glomerular filtration rate and renal blood flow. Compounds which antagonise the renal

30 affects of adenosine have potential as renal protective agents. Furthermore, adenosine A_3 and/or A_{2B} antagonists may be useful in the treatment of asthma and other allergic responses or and in the treatment of diabetes mellitus and obesity.

Numerous documents describe the current knowledge on adenosine receptors, for example the following publications:

- 35 Bioorganic & Medicinal Chemistry, 6, (1998), 619-641,
Bioorganic & Medicinal Chemistry, 6, (1998), 707-719,

- J. Med. Chem., (1998), 41, 2835-2845,
J. Med. Chem., (1998), 41, 3186-3201,
J. Med. Chem., (1998), 41, 2126-2133,
J. Med. Chem., (1999), 42, 706-721,
5 J. Med. Chem., (1996), 39, 1164-1171,
Arch. Pharm. Med. Chem., 332, 39-41, (1999),
Am. J. Physiol., 276, H1113-1116, (1999) or
Naunyn Schmied, Arch. Pharmacol. 362, 375-381, (2000).

Objects of the present invention are the compounds of formula IA and IB per se, the
10 use of compounds of formula IA and IB and their pharmaceutically acceptable salts for the
manufacture of medicaments for the treatment of diseases, related to the adenosine A₂
receptor, their manufacture, medicaments based on a compound in accordance with the
invention and their production as well as the use of compounds of formula IA and IB in
the control or prevention of illnesses based on the modulation of the adenosine system,
15 such as Alzheimer's disease, Parkinson's disease, Huntington's disease, neuroprotection,
schizophrenia, anxiety, pain, respiration deficits, depression, drug addiction, such as
amphetamine, cocaine, opioids, ethanol, nicotine, cannabinoids, or against asthma, allergic
responses, hypoxia, ischaemia, seizure and substance abuse. Furthermore, compounds of
the present invention may be useful as sedatives, muscle relaxants, antipsychotics,
20 antiepileptics, anticonvulsants and cardioprotective agents for disorders such as coronary
artery disease and heart failure. The most preferred indications in accordance with the
present invention are those, which base on the A_{2A} receptor antagonistic activity and which
include disorders of the central nervous system, for example the treatment or prevention of
Alzheimer's disease, certain depressive disorders, drug addiction, neuroprotection and
25 Parkinson's disease as well as ADHD.

As used herein, the term "lower alkyl" denotes a saturated straight- or branched-
chain alkyl group containing from 1 to 6 carbon atoms, for example, methyl, ethyl, propyl,
isopropyl, n-butyl, i-butyl, 2-butyl, t-butyl and the like. Preferred lower alkyl groups are
groups with 1 - 4 carbon atoms.

30 The term "cycloalkyl" denotes a saturated carbocyclic group, containing 4 - 6 carbon
atoms.

The term "halogen" denotes chlorine, iodine, fluorine and bromine.

The term "lower alkoxy" denotes a group wherein the alkyl residues is as defined
above, and which is attached via an oxygen atom.

The term "pharmaceutically acceptable acid addition salts" embraces salts with inorganic and organic acids, such as hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, citric acid, formic acid, fumaric acid, maleic acid, acetic acid, succinic acid, tartaric acid, methane-sulfonic acid, p-toluenesulfonic acid and the like.

- 5 Preferred compound of the present application are compounds of formula IA, wherein R¹ is morpholinyl and A is -O-. Particularly preferred are those compounds, wherein R is cycloalkyl, -(CH₂)_n-NHC(O)CH₃, -(CH₂)_n-N(R'')₂, -(CH₂)_n-O-lower alkyl or lower alkyl, for example the following compounds:

- 2-(2-methoxy-ethoxy)-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-
 10 isonicotinamide,
 2-ethoxy-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide,
 2-methoxy-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide,
 2-isopropoxy-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide,
 2-cyclohexyloxy-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide,
 15 2-cyclopentyloxy-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide,
 2-(2-dimethylamino-ethoxy)-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-
 isonicotinamide or
 2-(2-acetylamino-ethoxy)-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-
 isonicotinamide.

- 20 Further preferred are compounds of formula IA, wherein R¹ is morpholinyl, A is -O- and R is -(CH₂)_n-pyridinyl, -(CH₂)_n-morpholinyl or -(CH₂)_n-2-oxo-pyrrolidinyl, for example the following compounds:
 2-benzyloxy-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide,
 N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-(pyridin-2-ylmethoxy)-
 25 isonicotinamide,
 N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-[2-(2-oxo-pyrrolidin-1-yl)-
 ethoxy]-isonicotinamide or
 N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-(2-morpholin-4-yl-ethoxy)-
 isonicotinamide.

- 30 Further preferred are compounds of formula IA, wherein R¹ is morpholinyl, A is -NR'- and R is -(CH₂)_n-pyridinyl, -(CH₂)_n-piperidinyl, -(CH₂)_n-phenyl or -(CH₂)_n-morpholidinyl, for example the following compounds:
 N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-[methyl-(2-pyridin-2-yl-ethyl)-
 amino]-isonicotinamide,
 35 N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-(2-pyridin-2-yl-ethylamino)-

- isonicotinamide,
N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-[(pyridin-2-ylmethyl)-amino]-
 isonicotinamide,
 2-[ethyl-(2-pyridin-2-yl-ethyl)-amino]-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-
 5 yl)-isonicotinamide,
N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-(2-morpholin-4-yl-ethylamino)-
 isonicotinamide,
N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-[methyl-(2-piperidin-1-yl-ethyl)-
 amino]-isonicotinamide,
 10 *N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-(2-piperidin-1-yl-ethylamino)-
 isonicotinamide,
 2-benzylamino-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide,
 2-(benzyl-methyl-amino)-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-
 isonicotinamide,
 15 *N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-(methyl-phenethyl-amino)-
 isonicotinamide or
N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-phenethylamino-isonicotinamide.

- Further preferred are compounds of formula IA, wherein R¹ is morpholinyl, A is
 -NR' - and R is lower alkyl, cycloalkyl, -(CH₂)_n-O-lower alkyl, -(CH₂)_n-N(R'')₂ or
 20 -(CH₂)_n-NR''-C(O)-lower alkyl, for example the following compounds:
 2-[(2-methoxy-ethyl)-methyl-amino]-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-
 yl)-isonicotinamide,
 2-(2-methoxy-ethylamino)-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-
 isonicotinamide,
 25 2-[ethyl-(2-methoxy-ethyl)-amino]-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-
 isonicotinamide,
 2-(2-ethoxy-ethylamino)-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-
 isonicotinamide,
 2-(2-acetylamino-ethylamino)-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-
 30 isonicotinamide,
 2-cyclohexylamino-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide,
 2-cyclopentylamino-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-
 isonicotinamide,
 2-cyclobutylamino-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide,
 35 2-(2-dimethylamino-ethylamino)-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-
 isonicotinamide,
N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-propylamino-isonicotinamide,
N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-(methyl-propyl-amino)-

isonicotinamide,

2-(cyclohexyl-methyl-amino)-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-

isonicotinamide or

2-[(2-dimethylamino-ethyl)-methyl-amino]-*N*-(4-methoxy-7-morpholin-4-yl-

5 benzothiazol-2-yl)-isonicotinamide.

Further preferred are compounds of formula IA, wherein R¹ is morpholinyl, A is -CH₂- and R is -N(R'')-(CH₂)_m-O-lower alkyl, S-lower alkyl, -N(R'')₂, -N(R'')-(CH₂)_m-cycloalkyl or -N(R'')-(CH₂)_m-C(O)O-lower alkyl, for example the following compounds:

10 2-[(2-methoxy-ethylamino)-methyl]-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide,

2-[(2-ethoxy-ethylamino)-methyl]-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide,

2-[(butyl-methyl-amino)-methyl]-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-

15 isonicotinamide,

2-butylaminomethyl-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide,

2-diethylaminomethyl-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide,

20 *N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-methylaminomethyl-isonicotinamide,

2-ethylaminomethyl-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide,

25 2-[(cyclopropylmethyl-amino)-methyl]-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide,

4-{[4-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-carbamoyl)-pyridin-2-yl-methyl]-amino}-butyric acid tert-butyl ester,

[4-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-carbamoyl)-pyridin-2-ylmethyl]-methyl-carbamic acid methyl ester,

30 2-ethylsulfanylmethyl-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide,

2-[[[(2-ethoxy-ethyl)-methyl-amino]-methyl]-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide,

2-Ethylsulfanylmethyl-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-

35 isonicotinamide,

2-[[[(2-Ethoxy-ethyl)-methyl-amino]-methyl]-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

Preferred are further compounds of formula IA, wherein R¹ is morpholinyl, A is -CH₂- and R is pyrrolidinyl, -2-oxo-pyrrolidinyl, piperidinyl, which is optionally substituted by lower alkoxy or hydroxy, or is morpholinyl or alkoxy, for example the following compounds:

- 5 *N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-pyrrolidin-1-ylmethyl-isonicotinamide,
N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-(2-oxo-pyrrolidin-1-yl-methyl)-isonicotinamide,
N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-(4-methoxy-piperidin-1-ylmethyl)-isonicotinamide,
10 *N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-piperidin-1-ylmethyl-isonicotinamide,
2-(4-hydroxy-piperidin-1-ylmethyl)-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide,
15 *N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-morpholin-4-ylmethyl-isonicotinamide,
2-methoxymethyl-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide
or
2-(4-hydroxy-piperidin-1-yl-methyl)-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide
20

Preferred compound of the present application are compounds of formula IA, wherein R¹ is morpholinyl and A is -S-, for example the following compounds:
N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-methylsulfanyl-isonicotinamide or
2-ethylsulfanyl-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide.

- 25 Preferred compound of the present application are compounds of formula IA, wherein R¹ is morpholinyl and A - R are together -piperazinyl, substituted by lower alkyl, -C(O)-lower alkyl or an oxo group, or is piperidinyl, substituted by lower alkoxy or hydroxy, or is morpholinyl, substituted by lower alkyl, or is -cyclohexyl, -azetidin-1-yl, which is optionally substituted by hydroxy or lower alkoxy, or is -tetrahydropyran, or is 1,1-dioxo-thiomorpholinyl or 2-oxa-5-aza-bicyclo[2.2.1]hept-5-yl, for example the following compounds:
N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-(4-methyl-piperazin-1-yl)-isonicotinamide,
2-(4-acetyl-piperazin-1-yl)-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide,
35 *N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-(4-methyl-3-oxo-piperazin-1-yl)-isonicotinamide,

- 2-(4-ethyl-3-oxo-piperazin-1-yl)-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide,
 2-[(2*R*,6*S*)-2,6-dimethyl-morpholin-4-yl]-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide,
 5 2-cyclohexyl-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide,
 2-azetidin-1-yl-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide,
N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-(4-methoxy-piperidin-1-yl)-isonicotinamide,
N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-(3-methoxy-piperidin-1-yl)-
 10 isonicotinamide,
 2-(3-hydroxy-piperidin-1-yl)-*N*-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide,
N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-(tetrahydro-pyran-4-yl)-isonicotinamide,
 15 *N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-[(1*S*,4*S*)-2-oxa-5-aza-bicyclo[2.2.1]hept-5-yl]-isonicotinamide,
 2-(1,1-dioxo-1*H*-6-thiomorpholin-4-yl)-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide,
 2-(3-hydroxy-azetidin-1-yl)-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-
 20 isonicotinamide,
 2-(3-methoxy-azetidin-1-yl)-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide or
 2-(3-ethoxy-azetidin-1-yl)-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide.

25 Preferred compound of the present application are compounds of formula IA, wherein R¹ is piperidinyl and A – R are together piperazinyl, substituted by lower alkyl, for example the following compound

N-(4-methoxy-7-piperidin-1-yl-benzothiazol-2-yl)-2-(4-methyl-piperazin-1-yl)-isonicotinamide.

30 Preferred compound of the present application are compounds of formula IA, wherein R¹ is phenyl, A is –O– and R is lower alkyl, for example the following compound
 2-methoxy-*N*-(4-methoxy-7-phenyl-benzothiazol-2-yl)-isonicotinamide.

Preferred are further compounds of formula IA, wherein R¹ is piperidinyl. Especially preferred are those compounds, wherein A is –CH₂– and R is pyrrolidinyl or
 35 morpholidinyl, for example the following compounds:

N-(4-methoxy-7-piperidin-1-yl-benzothiazol-2-yl)-2-pyrrolidin-1-yl-methyl-isonicotinamide or

N-(4-methoxy-7-piperidin-1-yl-benzothiazol-2-yl)-2-morpholin-4-yl-methyl-isonicotinamide.


5

Compounds of formula IB are also preferred, for example those, wherein R¹ is morpholinyl, A is -O- and R is lower alkyl, -(CH₂)₂-O-lower alkyl or cycloalkyl, for example


- 6-methoxy-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-nicotinamide,
 10 6-isopropoxy-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-nicotinamide,
 6-(2-methoxy-ethoxy)-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-nicotinamide
 or
 6-cyclohexyloxy-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-nicotinamide.

- The present compounds of formulas IA and I-B and their pharmaceutically acceptable salts
 15 can be prepared by methods known in the art, for example, by processes described below, which processes comprise

a) reacting a compound of formula




(4A) or



(4B)


with a compound of formula

20




in the presence of a base

to a compound of formula



IA1 or




IB1


- 12 -

wherein R is $-(CH_2)_n-N(R'')-C(O)$ -lower alkyl, $-(CH_2)_n-O$ -lower alkyl,
 $-(CH_2)_n-O-(CH_2)_n-O$ -lower alkyl, lower alkyl, $-(CH_2)_n$ -morpholinyl,
 $-(CH_2)_n$ -phenyl, $-(CH_2)_n-N(R'')_2$, $-(CH_2)_n$ -pyridinyl, $-(CH_2)_n-CF_3$,
 $-(CH_2)_n$ -2-oxo-pyrrolidinyl or C_{4-6} -cycloalkyl, Y is chloro or bromo, A is O or S, and n is 1
 5 or 2;

b) reacting a compound of formula




(4A) or




(4B)


with a compound of formula



10 to a compound of formula



1A2 or




1B2


wherein R is lower alkyl, C_{4-6} -cycloalkyl, $-(CH_2)_n-O$ -lower alkyl, $-(CH_2)_n$ -pyridinyl,
 $-(CH_2)_n$ -piperidinyl, $-(CH_2)_n$ -phenyl, $-(CH_2)_n-N(R'')-C(O)$ -lower alkyl,
 $-(CH_2)_n$ -morpholinyl or $-(CH_2)_n-N(R'')_2$ or R and R' form together with the N atom the
 15 following groups: piperazinyl, optionally substituted by lower alkyl, $C(O)$ -lower alkyl or an
 oxo group, piperidinyl, optionally substituted by lower alkoxy or hydroxy, morpholinyl,
 optionally substituted by lower alkyl, azetidin-1-yl, optionally substituted by hydroxy or
 lower alkoxy, or thiomorpholine-1,1-dioxo or 2-oxa-bicyclo[2.2.1]hept-5-yl,
 R' and R'' are independently from each other hydrogen or lower alkyl, Y is chloro or
 20 bromo and n is 1 or 2; or

c) reacting a compound of formula

- 13 -



4A1 or




4B1


with a compound of formula

H-R (9)

to a compound of formula



IA3-1 or



IB3-1

5


wherein R is $-N(R'')-(CH_2)_m-O$ -lower alkyl, $-N(R'')_2$, -S-lower alkyl or is acetidinyl, pyrrolidinyl or piperidinyl, which are optionally substituted by hydroxy or lower alkoxy or is morpholinyl, $-N(R'')-(CH_2)_m-C_{4-6}$ -cycloalkyl,

$N(R'')-(CH_2)_m-C(O)O$ -lower alkyl, $-N(R'')-(CH_2)_m-C(O)OH$, -2-oxo-pyrrolidinyl,


10 $-N(R'')-C(O)O$ -lower alkyl, $-O(CH_2)_m-O$ -lower alkyl or alkoxy,

R'' is independently from each other hydrogen or lower alkyl and m is 1, 2 or 3, or

d) reacting a compound of formula



4A1 or



4B1


with a compound of formula

H-O-R (5)


15

to give a compound of formula

- 14 -




IA3-2 or




IB3-2

wherein R is $-(CH_2)_m-O$ -lower alkyl or is lower alkyl and m is 1, 2 or 3, or

e) reacting a compound of formula




(4A) or




(4B)


5 with a compound of formula



to a compound of formula



IA4 or




IB4


wherein A'-R are together C_{4-6} -cycloalkenyl or dihydropyran and Y is bromo,

10 and then reacting a compound of formula IA4 or IB4 with hydrogen and a catalyst to give a compound of formula

- 15 -



IA5 or



IB5

wherein A-R are together C₄₋₆-cycloalkyl or tetrahydropyran,

and

if desired, converting the compounds obtained into pharmaceutically acceptable acid
5 addition salts.

The compounds of formulae IA and IB may be prepared in accordance with process variants a) to e) and with the following schemes 1 to 10.

Preparation of compounds of formula IA or IB, wherein A is -O- or -S- and R is

-(CH₂)_n-N(R'')-C(O)-lower alkyl, -(CH₂)_n-O-lower alkyl,

10 -(CH₂)_n-O-(CH₂)_n-O-lower alkyl, lower alkyl, -(CH₂)_n-morpholinyl, -(CH₂)_n-phenyl,


-(CH₂)_n-N(R'')₂, -(CH₂)_n-pyridinyl, -(CH₂)_n-CF₃, -(CH₂)_n-2-oxo-pyrrolidinyl or

C₄₋₆-cycloalkyl and n is 1 or 2

One method of preparation of compounds of formula IA1 or IB1, wherein A is oxygen or sulfur, is from 2-chloro- or 2-bromo-isonicotinamide intermediates of formula
15 (4A) or from 2-chloro- or 2-bromo-nicotinamide intermediates of formula (4B), the preparation of which is shown in reaction schemes I and 2 below.

- 16 -


Scheme 1



- wherein R is $-(\text{CH}_2)_n\text{-N(R'')-C(O)-lower alkyl}$, $-(\text{CH}_2)_n\text{-O-lower alkyl}$,
 $-(\text{CH}_2)_n\text{-O-(CH}_2)_n\text{-O-lower alkyl}$, lower alkyl, $-(\text{CH}_2)_n\text{-morpholinyl}$, $-(\text{CH}_2)_n\text{-phenyl}$,
 5 $-(\text{CH}_2)_n\text{-N(R'')}_2$, $-(\text{CH}_2)_n\text{-pyridinyl}$, $-(\text{CH}_2)_n\text{-CF}_3$, $-(\text{CH}_2)_n\text{-2-oxo-pyrrolidinyl}$ or
 $\text{C}_{4-6}\text{-cycloalkyl}$, A is O or S, and n is 1 or 2.

HATU is O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate.

Scheme 2



IB1

wherein R is $-(\text{CH}_2)_n\text{-N(R'')-C(O)-lower alkyl}$, $-(\text{CH}_2)_n\text{-O-lower alkyl}$,
 $-(\text{CH}_2)_n\text{-O-(CH}_2)_n\text{-O-lower alkyl}$, lower alkyl, $-(\text{CH}_2)_n\text{-morpholinyl}$, $-(\text{CH}_2)_n\text{-phenyl}$,
 5 $-(\text{CH}_2)_n\text{-N(R'')}_2$, $-(\text{CH}_2)_n\text{-pyridinyl}$, $-(\text{CH}_2)_n\text{-CF}_3$, $-(\text{CH}_2)_n\text{-2-oxo-pyrrolidinyl}$ or
 $\text{C}_{4-6}\text{-cycloalkyl}$, A is O or S, and n is 1 or 2.

HATU is O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate.

Preparation of compounds of formula (2A) or (2B)

10 The starting 2-chloroisonicotinic acid or 2-bromoisonicotinic acid of formula (1A) or 2-chloronicotinic acid or 2-bromonicotinic acid of formula (1B) may be obtained

commercially, for example from Maybridge Chemicals, or may be prepared according to methods well known in the art.

The 2-haloisonicotinic acid of formula (1A) or 2-halonicotinic acid of formula (1B) may be converted to the corresponding acyl halide derivative of formula (2A) or (2B) by reacting a compound of formula (1A) or (1B) with an excess of a halogenating agent, such as oxalyl chloride or oxalyl bromide, or thionyl chloride or thionyl bromide, using a catalyst such as N,N-dimethylformamide or pyridine, in an organic solvent, preferably dichloromethane or dichloroethane, at room temperature for about 2-16 hours, preferably 16 hours. The product of formula (2) is isolated by conventional means, and preferably reacted in the next step without further purification.

Preparation of compounds of formula (4A) or (4B)

The starting 2-amino-benzothiazole compounds of formula (3) may be prepared according to methods disclosed in EP 00113219.0.

The compounds of formula (4A) or (4B) are prepared by treating the 2-amino-benzothiazole compounds of formula (3) with a slight excess of the acyl halide compounds of formula (2A) or (2B) in a non-protic organic solvent, preferably a mixture of dichloromethane and tetrahydrofuran, containing a base, preferably N-ethyl-diisopropylamine or triethylamine, at room temperature for 2-24 hours, preferably 24 hours. The product of formula (4A) or (4B) is isolated by conventional means, and preferably purified by means of chromatography or recrystallisation.

Alternative preparation of compounds of formula (4A) or (4B)

The compounds of formula (4A) or (4B) may also be prepared directly from compounds of formula (2A) or (2B). In this method, the compound of formula (2A) or (2B) is treated with a stoichiometric equivalent of a peptide-coupling reagent, preferably O-(7-azabenzotriazol-1-yl)-N,N',N'-tetramethyluronium hexafluorophosphate (HATU), in an ethereal solvent, preferably tetrahydrofuran, containing a base, preferably N-ethyl-diisopropylamine, at room temperature for 30-90 minutes. This mixture is then treated with a 2-amino-benzothiazole compound of formula (3) in a solvent mixture, preferably a mixture of tetrahydrofuran, dioxane and N,N-dimethylformamide, at room temperature for 16-24 hours, preferably 24 hours. The product of formula (4) is isolated by conventional means, and preferably purified by means of chromatography or recrystallisation.

Preparation of compounds of formula IA1 or IB1 (A is oxygen or sulfur)


One method of preparation of compounds of formula IA1 or IB1, is by treatment of a compound of formula (4A) or (4B) with an excess of an appropriate alcohol or thiol of formula (5), which may be commercially available or may be prepared by methods well known in the art, and which may be chosen from: a primary or secondary aliphatic alcohol or thiol, or an aromatic alcohol or thiol, in each case used together with a metal-hydride base, preferably sodium hydride or potassium hydride. These reactions may be carried out in an ethereal solvent such as such as dioxane, tetrahydrofuran or 1,2-dimethoxyethane, preferably dioxane, optionally containing a co-solvent such as N,N-dimethylformamide, at a temperature between room temperature and the reflux temperature of the solvent, preferably about 100 °C, for 2-72 hours, preferably 16 hours. The product of Formula I, where A is oxygen or sulfur, is isolated by conventional means, and preferably purified by means of chromatography or recrystallisation.

Preparation of compounds of formula IA2 and IB2, wherein A is -N(R')- and R is lower alkyl, C₄₋₆-cycloalkyl, -(CH₂)_n-O-lower alkyl, -(CH₂)_n-pyridinyl, -(CH₂)_n-piperidinyl, -(CH₂)_n-phenyl, -(CH₂)_n-N(R'')-C(O)-lower alkyl, -(CH₂)_n-morpholinyl or -(CH₂)_n-N(R'')₂ or R and R' form together with the N atom the following groups: piperazinyl, optionally substituted by lower alkyl, C(O)-lower alkyl or an oxo group, piperidinyl, optionally substituted by lower alkoxy or hydroxy, morpholinyl, optionally substituted by lower alkyl, azetidin-1-yl, optionally substituted by hydroxy or lower alkoxy, or thiomorpholine-1,1-dioxo or 2-oxa-bicyclo[2.2.1]hept-5-yl, R' and R'' are independently from each other hydrogen or lower alkyl, Y is bromo and n is 1 or 2

One method of preparation of compounds of formula IA1 and IB1 is from 2-bromo-isonicotinamide intermediates of formula (4A) or from 2-chloro- or 2-bromonicotinamide intermediates of formula (4B), as shown in reaction schemes 3 and 4 below.

- 20 -


Scheme 3



- R is lower alkyl, C₄₋₆-cycloalkyl, -(CH₂)_n-O-lower alkyl, -(CH₂)_n-pyridinyl, -(CH₂)_n-piperidinyl, -(CH₂)_n-phenyl, -(CH₂)_n-N(R'')-C(O)-lower alkyl, -(CH₂)_n-morpholinyl or -(CH₂)_n-N(R'')₂ or R and R' form together with the N atom the following groups: piperazinyl, optionally substituted by lower alkyl, C(O)-lower alkyl or an oxo group, piperidinyl, optionally substituted by lower alkoxy or hydroxy, morpholinyl, optionally substituted by lower alkyl, azetidin-1-yl, optionally substituted by hydroxy or lower alkoxy, or thiomorpholine-1,1-dioxo or 2-oxa-bicyclo[2.2.1]hept-5-yl.
- R' and R'' are independently from each other hydrogen or lower alkyl, Y is bromo, R' and R'' are independently from each other hydrogen or lower alkyl and n is 1 or 2.

- 21 -

Scheme 4



- R is lower alkyl, C₄₋₆-cycloalkyl, -(CH₂)_n-O-lower alkyl, -(CH₂)_n-pyridinyl, -(CH₂)_n-piperidinyl, -(CH₂)_n-phenyl, -(CH₂)_n-N(R'')-C(O)-lower alkyl,
- 5 -(CH₂)_n-morpholinyl or -(CH₂)_n-N(R'')₂ or R and R' form together with the N atom the following groups: piperazinyl, optionally substituted by lower alkyl, C(O)-lower alkyl or an oxo group, piperidinyl, optionally substituted by lower alkoxy or hydroxy, morpholinyl, optionally substituted by lower alkyl, azetidin-1-yl, optionally substituted by hydroxy or lower alkoxy, or thiomorpholine-1,1-dioxo or 2-oxa-bicyclo[2.2.1]hept-5-yl,
- 10 R' and R'' are independently from each other hydrogen or lower alkyl, Y is chloro or bromo, R' and R'' are independently from each other hydrogen or lower alkyl and n is 1 or 2.

To prepare the compounds of formula IA2 or IB2, the 2-bromo-isonicotinamide intermediate of formula (4A) or the 2-chloro- or 2-bromo-nicotinamide intermediate of formula (4B) is treated with a large excess of an appropriate amine of formula (6), which


15 may be commercially available or may be prepared by methods well known in the art, and which may be chosen from: a primary or secondary aliphatic amine or an aromatic amine, in each case used together with a metal carbonate base, preferably cesium carbonate. These

reactions may be carried out in the absence of added solvent, or optionally in the presence of a solvent such as N,N-dimethylformamide or N-methylpyrrolidone, at an elevated temperature, preferably about 140 °C, for 2-48 hours, preferably 24 hours. The product of formula IA2 or IB2, where A is nitrogen, is isolated by conventional means, and preferably purified by means of chromatography or recrystallisation.

Preparation of compounds of formula IA or IB, wherein A is -CH₂- and R is -N(R'')-(CH₂)_m-O-lower alkyl, -N(R'')₂, -S-lower alkyl or is acetidinyl, pyrrolidinyl or piperidinyl, which are optionally substituted by hydroxy or lower alkoxy or is morpholinyl, -N(R'')-(CH₂)_m-C₄₋₆-cycloalkyl, -N(R'')-(CH₂)_m-C(O)O-lower alkyl, -N(R'')-(CH₂)_m-C(O)OH, -2-oxo-pyrrolidinyl, -N(R'')-C(O)O-lower alkyl, -O(CH₂)_m-O-lower alkyl or alkoxy, R'' is independently from each other hydrogen or lower alkyl and m is 1, 2 or 3;

One method of preparation of compounds of formula IA or IB, wherein A is CH₂, is from 2-chloromethyl-isonicotinamide intermediates of formula (4A1) or from 2-chloromethyl-nicotinamide intermediates of formula (4B1), as shown in reaction scheme 5 and 6 below.


Scheme 5



wherein R in this scheme for compounds of formula IA3-1 is -N(R'')-(CH₂)_m-O-lower alkyl, -N(R'')₂, -S-lower alkyl or is acetidinyl, pyrrolidinyl or piperidinyl, which are

- optionally substituted by hydroxy or lower alkoxy, or is morpholinyl,
 $-N(R'')-(CH_2)_m-C_{4-6}\text{-cycloalkyl}$, $N(R'')-(CH_2)_m-C(O)O\text{-lower alkyl}$,
 $-N(R'')-(CH_2)_m-C(O)OH$, -2-oxo-pyrrolidinyl or $-N(R'')-C(O)O\text{-lower alkyl}$,
 R'' is independently from each other hydrogen or lower alkyl and m is 1, 2 or 3, and R in
 5 this scheme for compounds of formula IA3-2 is $-(CH_2)_m-O\text{-lower alkyl}$ or alkyl;


Scheme 6




- wherein R in this scheme for compounds of formula IB3-1 is $-N(R'')-(CH_2)_m-O\text{-lower}$
 10 alkyl, $-N(R'')_2$, -S-lower alkyl or is acetidinyl, pyrrolidinyl or piperidinyl, which are
 optionally substituted by hydroxy or lower alkoxy, or is morpholinyl,
 $-N(R'')-(CH_2)_m-C_{4-6}\text{-cycloalkyl}$, $N(R'')-(CH_2)_m-C(O)O\text{-lower alkyl}$,
 $-N(R'')-(CH_2)_m-C(O)OH$, -2-oxo-pyrrolidinyl, $-N(R'')-C(O)O\text{-lower alkyl}$,
 R'' is independently from each other hydrogen or lower alkyl and m is 1, 2 or 3, and R in
 15 this scheme for compounds of formula IB3-2 is $-(CH_2)_m-O\text{-lower alkyl}$ or alkyl,
 R'' is hydrogen or lower alkyl, and m is 1, 2 or 3.

- One method of preparation of compounds of formulae IA3-1 or IA3-2 and IB3-1 or
 IB3-2 is from the appropriately substituted benzothiazol-2-yl-amine (3) and 2-
 chloromethyl-isonicotinoyl chloride (4A1) or 2-chloromethyl-nicotinoyl chloride (4B1) as
 20 shown in reaction schemes 7 and 8 below.

Scheme 7



Scheme 8



5 Preparation of compounds of formula IA or IB, wherein A is -CH₂- and R is -O(CH₂)_m-O-lower alkyl or alkoxy

One method of preparation of compounds of formula IA3-1, IA3-2, IB3-1 or IB3-2 is by treatment of a compound of formula (4A1) or (4B1) with an excess of an appropriate alcohol of formula (5), which may be commercially available or may be prepared by methods well known in the art, and which may be chosen from: a primary or secondary aliphatic alcohol or an aromatic alcohol, in each case used together with a metal-hydride base, preferably sodium hydride or potassium hydride. These reactions may be carried out in an ethereal solvent such as dioxane, tetrahydrofuran or 1,2-dimethoxyethane, preferably dioxane, optionally containing a co-solvent such as *N,N*-dimethylformamide, or in the respective alcohol as solvent, at a temperature between room temperature and the reflux temperature of the solvent, preferably about 100 °C, for 2-72 hours, preferably 16 hours. The product of Formula I, where A is CH₂O, is isolated by conventional means, and preferably purified by means of chromatography or recrystallisation.

20 Preparation of compounds of formula IA or IB, wherein A is -CH₂- and R is -N(R'')-(CH₂)_m-O-lower alkyl, -N(R'')₂, or is acetidinyl, pyrrolidinyl or piperidinyl, which are optionally substituted by hydroxy or lower alkoxy or is morpholinyl, -N(R'')-(CH₂)_m-C₄₋₆-cycloalkyl, -N(R'')-(CH₂)_m-C(O)O-lower alkyl,

-N(R'')-(CH₂)_m-C(O)OH, -2-oxo-pyrrolidinyl, -N(R'')-C(O)O-lower alkyl,
R'' is independently from each other hydrogen or lower alkyl and m is 1, 2 or 3


To prepare the compounds of formula IA or IB, wherein A is -CH₂-, the 2-chloro-isonicotinamide intermediate of formula (4A1) or (4B1) is treated with a large excess of an
5 appropriate amine of formula (9), which may be commercially available or may be prepared by methods well known in the art, and which may be chosen from: a primary or secondary aliphatic amine or an aromatic amine. These reactions may be carried out in the absence of added solvent, or optionally in the presence of a solvent such as *N,N*-dimethylformamide or *N*-methylpyrrolidone, at an elevated temperature, preferably about
10 60 °C, for 2-48 hours, preferably 4 hours. The product of formula I, where A is CH₂, is isolated by conventional means, and preferably purified by means of chromatography or recrystallisation.

Preparation of compounds of formula I, wherein A-R are together C₄₋₆-cycloalkyl or tetrahydropyran.

15 One method of preparation of compounds of formula IA4 or IB4 and IA5 or IB5 is shown in reaction schemes 9 and 10 below.


- 26 -

Scheme 9



wherein A'-R are together C₄₋₆-cycloalkenyl or dihydropyran and A-R are together C₄₋₆-cycloalkyl or tetrahydropyran.

Scheme 10



wherein A'-R are together C₄₋₆-cycloalkenyl or dihydropyran and A-R are together C₄₋₆-cycloalkyl or tetrahydropyran.

5 Preparation of compounds of formula IA4 and IB4

The starting tributylstannane compounds of formula (7) may be obtained commercially, for example from Fluka, or may be prepared according to methods well known in the art.

- 10 The compounds of formula IA4 or IB4 are prepared by treating 2-bromo-isonicotinamide intermediates of formula (4A) or 2-bromo-nicotinamide intermediates of formula (4B) with an excess of a tributylstannane compound of formula (7) in an organic solvent, preferably *N,N*-dimethylformamide, containing a palladium catalyst, preferably bis(triphenylphosphine)palladium(II) chloride, and in the presence of other additives such

as triphenylphosphine, lithium chloride and 2,6-di-*tert*-butyl-4-methylphenol. The reaction is carried out at elevated temperature, preferably about 100 °C, for about 16-96 hours, preferably about 72 hours. The product of formula IA4 or IB4 is isolated by conventional means, and preferably purified by means of chromatography or
5 recrystallisation.

Alternative preparation of compounds of formula IA4 or IB4

The starting boronic acid compounds of formula (8) may be obtained commercially, for example from Fluka, or may be prepared according to methods well known in the art.

The compounds of formula IA4 or IB4 may alternatively be prepared by treating 2-
10 bromo-isonicotinamide intermediates of formula (4A) or 2-bromo-nicotinamide intermediates of formula (4B) with an excess of a boronic acid compound of formula (8). The reaction is carried out in an aqueous solvent, preferably a mixture of water and dioxane, containing a palladium catalyst, preferably bis(triphenylphosphine)palladium(II) chloride, and an inorganic base, preferably sodium carbonate. The reaction is preferably
15 carried out in the presence of other additives such as triphenylphosphine, lithium chloride and 2,6-di-*tert*-butyl-4-methylphenol. The reaction is preferably carried out at the reflux temperature of the solvent, preferably about 100 °C, for about 16-96 hours, preferably about 48 hours. The product of formula IA4 or IB4 is isolated by conventional means, and preferably purified by means of chromatography or recrystallisation.

20 Preparation of compounds of formula IA5 and IB5

One method of preparation of compounds of formula IA5 or IB5 is by hydrogenation of a compound of formula IA4 or IB4 in the presence of a hydrogenation catalyst, preferably 10 % palladium on charcoal. These reactions may be carried out in a mixture of organic solvents, preferably a mixture of methanol and dichloromethane, at room temperature and
25 at a pressure of one atmosphere or above, preferably at one atmosphere, for 2-48 hours, preferably about 16 hours. The product of formula IA5 or IB5, where A is carbon, is isolated by conventional means, and preferably purified by means of chromatography or recrystallisation.

Isolation and purification of the compounds

30 Isolation and purification of the compounds and intermediates described herein can be effected, if desired, by any suitable separation or purification procedure such as, for example, filtration, extraction, crystallization, column chromatography, thin-layer chromatography, thick-layer chromatography, preparative low or high-pressure liquid chromatography or a combination of these procedures. Specific illustrations of suitable

separation and isolation procedures can be had by reference to the Preparations and Examples herein below. However, other equivalent separation or isolation procedures could, of course, also be used.

Salts of compounds of formula IA and IB

- 5 The compounds of Formula IA or IB may be basic, for example in cases where the residue A-R contains a basic group such as an aliphatic or aromatic amine moiety. In such cases the compounds of Formula IA or IB may be converted to a corresponding acid addition salt.

10 The conversion is accomplished by treatment with at least a stoichiometric amount of an appropriate acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like. Typically, the
15 free base is dissolved in an inert organic solvent such as diethyl ether, ethyl acetate, chloroform, ethanol or methanol and the like, and the acid added in a similar solvent. The temperature is maintained between 0 °C and 50 °C. The resulting salt precipitates spontaneously or may be brought out of solution with a less polar solvent.

20 The acid addition salts of the basic compounds of Formula IA and IB may be converted to the corresponding free bases by treatment with at least a stoichiometric equivalent of a suitable base such as sodium or potassium hydroxide, potassium carbonate, sodium bicarbonate, ammonia, and the like.

25 The compounds of formulas IA and IB and their pharmaceutically usable addition salts possess valuable pharmacological properties. Specifically, it has been found that the compounds of the present invention are adenosine receptor ligands and possess a high affinity towards the adenosine A_{2A} receptor.

The compounds were investigated in accordance with the test given hereinafter.

Human adenosine A_{2A} receptor

30 The human adenosine A_{2A} receptor was recombinantly expressed in chinese hamster ovary (CHO) cells using the semliki forest virus expression system. Cells were harvested, washed twice by centrifugation, homogenised and again washed by centrifugation. The final washed membrane pellet was suspended in a Tris (50 mM) buffer containing 120 mM NaCl, 5 mM KCl, 2 mM CaCl₂ and 10 mM MgCl₂ (pH 7.4) (buffer A). The [³H]-SCH-

58261 (Dionisotti et al., 1997, Br J Pharmacol 121, 353; 1nM) binding assay was carried out in 96-well plates in the presence of 2.5 µg of membrane protein, 0.5 mg of Ysi-poly-l-lysine SPA beads and 0.1 U adenosine deaminase in a final volume of 200 µl of buffer A. Non-specific binding was defined using xanthine amine congener (XAC; 2 µM). Compounds were tested at 10 concentrations from 10 µM - 0.3 nM. All assays were conducted in duplicate and repeated at least two times. Assay plates were incubated for 1 hour at room temperature before centrifugation and then bound ligand determined using a Packard Topcount scintillation counter. IC₅₀ values were calculated using a non-linear curve fitting program and K_i values calculated using the Cheng-Prusoff equation.

10 The preferred compounds show a pK_i > 8.5. In the list below are described some affinity data to the hA₂-receptor:

Example No.	hA ₂ (pK _i)	Example No.	hA ₂ (pK _i)
1	8.50	73	8.74
3	8.51	74	8.87
4	8.58	75	8.72
5	8.58	76	8.76
6	8.94	77	8.54
8	8.75	80	8.68
10	9.14	81	8.62
13	8.81	83	8.76
15	8.72	85	8.53
17	8.63	86	9.30
18	9.21	87	9.07
24	8.65	88	9.34
26	9.02	89	8.83
31	9.00	90	8.76

35	8.70	92	8.80
40	8.99	93	8.97
44	8.52	94	8.92
47	8.6	95	8.72
52	8.8	96	8.79
54	8.7	97	8.65
56	8.8	99	9.22
58	8.7	100	8.81
62	8.8	101	8.90
65	8.5	102	8.70
70	8.9	103	8.80
71	8.7	104	8.50

The compounds of formula IA and IB and the pharmaceutically acceptable salts of the compounds of formula IA and IB can be used as medicaments, e.g. in the form of pharmaceutical preparations. The pharmaceutical preparations can be administered orally, e.g. in the form of tablets, coated tablets, dragées, hard and soft gelatine capsules, solutions, emulsions or suspensions. The administration can, however, also be effected rectally, e.g. in the form of suppositories, parenterally, e.g. in the form of injection solutions.

The compounds of formula IA and IB can be processed with pharmaceutically inert, inorganic or organic carriers for the production of pharmaceutical preparations. Lactose, corn starch or derivatives thereof, talc, stearic acids or its salts and the like can be used, for example, as such carriers for tablets, coated tablets, dragées and hard gelatine capsules. Suitable carriers for soft gelatine capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like. Depending on the nature of the active substance no carriers are, however, usually required in the case of soft gelatine capsules. Suitable carriers for the production of solutions and syrups are, for example, water, polyols, glycerol, vegetable oil and the like. Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like.

The pharmaceutical preparations can, moreover, contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.

5 Medicaments containing a compound of formula IA and IB or a pharmaceutically acceptable salt thereof and a therapeutically inert carrier are also an object of the present invention, as is a process for their production, which comprises bringing one or more compounds of formula IA and IB and/or pharmaceutically acceptable acid addition salts and, if desired, one or more other therapeutically valuable substances into a galenical
10 administration form together with one or more therapeutically inert carriers.

In accordance with the invention compounds of formula IA and IB as well as their pharmaceutically acceptable salts are useful in the control or prevention of illnesses based on the adenosine receptor antagonistic activity, such as Alzheimer's disease, Parkinson's disease, neuroprotection, schizophrenia, anxiety, pain, respiration deficits, depression,
15 asthma, allergic responses, hypoxia, ischaemia, seizure and substance abuse. Furthermore, compounds of the present invention may be useful as sedatives, muscle relaxants, antipsychotics, antiepileptics, anticonvulsants and cardioprotective agents and for the production of corresponding medicaments.

The most preferred indications in accordance with the present invention are those,
20 which include disorders of the central nervous system, for example the treatment or prevention of certain depressive disorders, neuroprotection and Parkinson's disease.

The dosage can vary within wide limits and will, of course, have to be adjusted to the individual requirements in each particular case. In the case of oral administration the dosage for adults can vary from about 0.01 mg to about 1000 mg per day of a compound of
25 general formula I or of the corresponding amount of a pharmaceutically acceptable salt thereof. The daily dosage may be administered as single dose or in divided doses and, in addition, the upper limit can also be exceeded when this is found to be indicated.

Tablet Formulation (Wet Granulation)

<u>Item</u>	<u>Ingredients</u>	<u>mg/tablet</u>			
		5 mg	25 mg	100 mg	500 mg
1.	Compound of formula IA or IB	5	25	100	500
5 2.	Lactose Anhydrous DTG	125	105	30	150
3.	Sta-Rx 1500	6	6	6	30
4.	Microcrystalline Cellulose	30	30	30	150
5.	Magnesium Stearate	1	1	1	1
	Total	167	167	167	831

10 Manufacturing Procedure

1. Mix items 1, 2, 3 and 4 and granulate with purified water.
2. Dry the granules at 50°C.
3. Pass the granules through suitable milling equipment.
4. Add item 5 and mix for three minutes; compress on a suitable press.

15

Capsule Formulation

<u>Item</u>	<u>Ingredients</u>	<u>mg/capsule</u>			
		5 mg	25 mg	100 mg	500 mg
1.	Compound of formula IA or IB	5	25	100	500
20 2.	Hydrous Lactose	159	123	148	---
3.	Corn Starch	25	35	40	70
4.	Talc	10	15	10	25
5.	Magnesium Stearate	1	2	2	5
	Total	200	200	300	600

25 Manufacturing Procedure

1. Mix items 1, 2 and 3 in a suitable mixer for 30 minutes.
2. Add items 4 and 5 and mix for 3 minutes.
3. Fill into a suitable capsule.

The following preparation and examples illustrate the invention but are not intended to limit its scope.

Example 1

5 2-(2-Methoxy-ethoxy)-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

a) 2-Chloro-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

To a stirred solution of 10.8 g (40.8 mmol) 4-methoxy-7-morpholin-4-yl-benzothiazol-2-ylamine and 17.3 ml (102 mmol) N-ethyldiisopropylamine in 500 ml THF at 5 °C was added dropwise over 90 minutes a solution of 7.90 g (44.9 mmol) 2-chloro-isonicotinoyl chloride in 250 ml dichloromethane and stirring continued at room temperature for 16 h. The reaction mixture was then quenched by addition of 30 ml methanol and concentrated *in vacuo*. The residue was then resuspended in ethyl acetate and washed sequentially with saturated sodium bicarbonate solution, 0.5 M hydrochloric acid and saturated brine. The organic phase was then dried over sodium sulfate and concentrated *in vacuo* to ca 100 ml. The resulting suspension was then left standing at room temperature for 72 h and then 100 ml ether was added and the suspension stirred for 1 hour at room temperature. The crystals were collected by filtration and dried *in vacuo* to afford 9.79 g (59%) 2-chloro-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide as a brown crystalline solid. ES-MS m/e (%): 429 (M{³⁷Cl}+Na⁺, 11), 427 (M{³⁵Cl}+Na⁺, 30), 407 (M{³⁷Cl}+H⁺, 30), 405 (M{³⁵Cl}+H⁺, 100).

b) 2-(2-Methoxy-ethoxy)-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

To a stirred solution of 0.058 ml (0.74 mmol) 2-methoxyethanol in 2 ml dioxane at room temperature was added 49 mg (1.24 mmol) sodium hydride (60% dispersion in mineral oil) and stirring continued for 10 minutes. 200 mg (0.49 mmol) 2-chloro-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide was then added and the mixture heated at 115 °C for 16 h. The reaction mixture was then cooled to room temperature, diluted with ethyl acetate, and washed sequentially with 1 M hydrochloric acid and saturated brine. The organic phase was then dried over sodium sulfate and concentrated *in vacuo*. Flash chromatography (2/1 ethyl acetate/toluene) afforded 109 mg (50%) 2-(2-methoxy-ethoxy)-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide as a yellow crystalline solid. ES-MS m/e (%): 467 (M+Na⁺, 16), 445 (M+H⁺, 100).

In an analogous manner there was obtained:

Example 2

2-[2-(2-Methoxy-ethoxy)-ethoxy]-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

- From 2-chloro-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide with sodium hydride and diethylene glycol monomethyl ether in dioxane. ES-MS m/e (%): 511 (M+Na⁺, 13), 489 (M+H⁺, 100).

Example 3

2-Ethoxy-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

a) 2-Bromo-isonicotinic acid

- To a stirred solution of 29.0 g (169 mmol) 2-bromo-4-methylpyridine in 150 ml concentrated sulfuric acid was added portionwise 67.9 g (231 mmol) potassium dichromate and the reaction mixture was cooled with an ice bath so that the temperature stayed between 20-50 °C. After the addition was complete, stirring was continued at room temperature for a further 2 h. The reaction mixture was then poured slowly onto 2 l ice-water and the mixture stirred for 1 hour at room temperature. The resulting crystals were collected by filtration, washed with water until the washings were colourless, and dried *in vacuo* to afford 30.0 g (88%) 2-bromo-isonicotinic acid as a white crystalline solid. EI-MS m/e (%): 203 (M{⁸¹Br}⁺, 100), 201 (M{⁷⁹Br}⁺, 93). 122 ([M-Br]⁺, 98).

b) 2-Bromo-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

- To a stirred solution of 3.81 g (18.8 mmol) 2-bromo-isonicotinic acid in 50 ml THF were added 7.16 g (18.8 mmol) HATU and 3.21 ml (18.8 mmol) N-ethyl-diisopropylamine and stirring continued at room temperature for 90 minutes. A solution of 5.00 g (18.8 mmol) 4-methoxy-7-morpholin-4-yl-benzothiazol-2-ylamine in 50 ml dioxane and 10 ml DMF was then added and stirring continued at room temperature for 16 h. The reaction mixture was then poured into 300 ml 1 M hydrochloric acid and the mixture stirred for 20 min. The resulting crystals were collected by filtration, washed with water and then with ether, and dried *in vacuo* to afford 7.53 g (89%) 2-bromo-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide as a yellow crystalline solid. ES-MS m/e (%): 473 (M{⁸¹Br}+Na⁺, 30), 471 (M{⁷⁹Br}+Na⁺, 34). 451 (M{⁸¹Br}+H⁺, 100), 449 (M{⁷⁹Br}+H⁺, 80).

c) 2-Ethoxy-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

To a stirred solution of 0.52 ml (8.90 mmol) ethanol in 30 ml dioxane at room temperature was added 486 mg (11.1 mmol) sodium hydride (55% dispersion in mineral oil) and the mixture heated at 50 °C for 30 minutes. 1.00 g (2.23 mmol) 2-bromo-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide was then added and the mixture heated at 115 °C for 72 h. The reaction mixture was then cooled to room temperature and concentrated *in vacuo*. The residue was resuspended in dichloromethane, and washed sequentially with water and saturated brine. The organic phase was then dried over sodium sulfate and concentrated *in vacuo*. The residue was resuspended in methanol and concentrated *in vacuo* to 2 ml, 20 ml ether added, and the resulting crystals were collected by filtration and dried *in vacuo* to afford 410 mg (44%) 2-ethoxy-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide as a light yellow crystalline solid. ES-MS *m/e* (%): 437 ($M+Na^+$, 24), 414 ($M+H^+$, 100).

Analogously to Example 1 there were obtained:

Example 4

15 2-Benzoyloxy-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

From 2-chloro-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide with sodium hydride and benzyl alcohol in dioxane. ES-MS *m/e* (%): 499 ($M+Na^+$, 40), 477 ($M+H^+$, 100).

Example 5

20 2-Methoxy-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

From 2-chloro-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide with sodium hydride and methanol in dioxane and DMF. ES-MS *m/e* (%): 423 ($M+Na^+$, 31), 401 ($M+H^+$, 100).

Example 6

25 *N*-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-(pyridin-2-ylmethoxy)-isonicotinamide

From 2-chloro-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide with sodium hydride and 2-hydroxymethylpyridine in dioxane. ES-MS *m/e* (%): 500 ($M+Na^+$, 23), 478 ($M+H^+$, 100).

Example 7

N-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-[methyl-(2-pyridin-2-yl-ethyl)-amino]-isonicotinamide

A stirred suspension of 200 mg (0.45 mmol) 2-bromo-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide, 1.23 ml (8.90 mmol) 2-(2-methylaminoethyl)pyridine and 290mg (0.89 mmol) cesium carbonate in a thick-walled glass pressure tube fitted with a teflon cap was heated at 140 °C for 24 h. The reaction mixture was then cooled to room temperature and poured onto water. The mixture was extracted three times with dichloromethane, and the combined organic phases were washed with saturated brine, dried over sodium sulfate, and concentrated *in vacuo*. Flash chromatography (0/100-2.5/97.5 methanol/dichlormoethane) followed by trituration in ether afforded 160 mg (71%) *N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-[methyl-(2-pyridin-2-yl-ethyl)-amino]-isonicotinamide as a light yellow crystalline solid. ES-MS *m/e* (%): 505 ($M+H^+$, 100).

In an analogous manner there were obtained:

Example 8

N-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-(2-pyridin-2-yl-ethylamino)-isonicotinamide

From 2-bromo-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide with cesium carbonate and 2-(2-aminoethyl)-pyridine in NMP. ES-MS *m/e* (%): 491 ($M+H^+$, 100).

Example 9

2-[(2-Methoxy-ethyl)-methyl-amino]-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

From 2-bromo-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide with cesium carbonate and *N*-(2-methoxyethyl)-methylamine. ES-MS *m/e* (%): 458 ($M+H^+$, 100).

Example 10

N-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-(4-methyl-piperazin-1-yl)-isonicotinamide

From 2-bromo-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide with cesium carbonate and 1-methylpiperazine. ES-MS *m/e* (%): 469 ($M+H^+$, 100).

Example 11

5 2-(2-Methoxy-ethylamino)-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

From 2-bromo-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide with cesium carbonate and 2-methoxyethylamine. ES-MS *m/e* (%): 444 ($M+H^+$, 100).

Example 12

10 2-(4-Acetyl-piperazin-1-yl)-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

From 2-bromo-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide with cesium carbonate and 1-acetylpiperazine. ES-MS *m/e* (%): 519 ($M+Na^+$, 32), 497 ($M+H^+$, 100).

Example 13

15 *N*-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-[(pyridin-2-ylmethyl)-amino]-isonicotinamide

From 2-bromo-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide with cesium carbonate and 2-picolyamine. ES-MS *m/e* (%): 477 ($M+H^+$, 100).

Example 14

20 *N*-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-[methyl-(2-piperidin-1-yl-ethyl)-amino]-isonicotinamide

From 2-bromo-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide with cesium carbonate and methyl-(2-piperidin-1-yl-ethyl)-amine. ES-MS *m/e* (%): 511 ($M+H^+$, 100).

25

Example 15

2-(2-Acetyl-amino-ethylamino)-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

From 2-bromo-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide with cesium carbonate and *N*-acetyl-ethylenediamine. ES-MS *m/e* (%): 493 ($M+Na^+$, 19), 471 ($M+H^+$, 100).

Analogously to Example 1 there were obtained:

5

Example 16

N-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-(2,2,2-trifluoro-ethoxy)-isonicotinamide

From 2-chloro-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide with sodium hydride and 2,2,2-trifluoroethanol in dioxane and DMF. ES-MS *m/e* (%): 491
10 ($M+Na^+$, 81), 469 ($M+H^+$, 100).

Example 17

N-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-[2-(2-oxo-pyrrolidin-1-yl)-ethoxy]-isonicotinamide

From 2-chloro-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide with
15 sodium hydride and 1-(2-hydroxyethyl)-2-pyrrolidone in dioxane. ES-MS *m/e* (%): 520 ($M+Na^+$, 47), 498 ($M+H^+$, 100).

Analogously to Example 7 there were obtained:

Example 18

N-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-(2-morpholin-4-yl-ethylamino)-
20 isonicotinamide

From 2-bromo-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide with cesium carbonate and 4-(2-aminoethyl)-morpholine. ES-MS *m/e* (%): 499 ($M+H^+$, 100).

Example 19

N-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-(2-piperidin-1-yl-ethylamino)-
25 isonicotinamide

From 2-bromo-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide with cesium carbonate and 1-(2-aminoethyl)-piperidine. ES-MS *m/e* (%): 497 ($M+H^+$, 100).

Example 20

2-[Ethyl-(2-pyridin-2-yl-ethyl)-amino]-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

- From 2-bromo-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide with cesium carbonate and 2-[2-(ethylamino)ethyl]pyridine. ES-MS *m/e* (%): 519 ($M+H^+$, 100).

Example 21

2-[Ethyl-(2-methoxy-ethyl)-amino]-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

- From 2-bromo-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide with cesium carbonate and *N*-(2-methoxyethyl)ethylamine. ES-MS *m/e* (%): 472 ($M+H^+$, 100).

Example 22

2-(2-Ethoxy-ethylamino)-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

- From 2-bromo-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide with cesium carbonate and 2-ethoxyethylamine. ES-MS *m/e* (%): 458 ($M+H^+$, 100).

Example 23

2-[(2*R*,6*S*)-2,6-Dimethyl-morpholin-4-yl]-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

- From 2-bromo-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide with cesium carbonate and *cis*-2,6-dimethylmorpholine. ES-MS *m/e* (%):

Example 24

2-Cyclohexyl-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

- a) 2-Cyclohex-1-enyl-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

To a stirred solution of 400 mg (0.89 mmol) 2-bromo-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide in 10 ml DMF were added 661 mg (1.78 mmol) tri-*n*-butyl-cyclohex-1-enyl-stannane, 75 mg (0.11 mmol) bis(triphenylphosphine)palladium(II) chloride, 140 mg (0.53 mmol) triphenylphosphine, 317 mg (7.48 mmol) lithium chloride

and a small spatula-end of 2,6-di-*tert*-butyl-4-methylphenol. The mixture was heated at 100 °C for 72 h and then concentrated *in vacuo*. Rough flash chromatography (2/98 methanol/dichloromethane) afforded 520 mg of an orange solid, comprising mainly 2-cyclohex-1-enyl-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide, which was taken onto the next reaction step without further purification. ES-MS *m/e* (%): 451 ($M+H^+$, 100).

b) 2-Cyclohexyl-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

To a stirred solution of 585 mg (theoretically max 1.30 mmol) crude 2-cyclohex-1-enyl-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide in 5 ml methanol and 10 ml dichloromethane was added 500 mg 10% palladium on charcoal and the mixture was then stirred for 16 h at room temperature under an atmosphere of hydrogen. The mixture was then filtered, washing with dichloromethane, and the filtrate concentrated *in vacuo*. Flash chromatography (1/19 methanol/dichloromethane) followed by trituration in ether and pentane afforded 125 mg (21%) 2-cyclohexyl-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide as an off-white crystalline solid. ES-MS *m/e* (%): 475 ($M+Na^+$, 26), 453 ($M+H^+$, 100).

Analogously to Example 7 there were obtained:

Example 25

N-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-(4-methyl-3-oxo-piperazin-1-yl)-isonicotinamide

From 2-bromo-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide with cesium carbonate and 1-methyl-piperazin-2-one. ES-MS *m/e* (%): 505 ($M+Na^+$, 31), 483 ($M+H^+$, 100).

Example 26

2-Azetidin-1-yl-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

From 2-bromo-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide with cesium carbonate and azetidine. ES-MS *m/e* (%): 426 ($M+H^+$, 100).

Example 27

N-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-(4-methoxy-piperidin-1-yl)-isonicotinamide

From 2-bromo-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide with cesium carbonate and 4-methoxy-piperidine. ES-MS *m/e* (%): 484 ($M+H^+$, 100).

Example 28

- 5 *N*-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-(3-methoxy-piperidin-1-yl)-isonicotinamide

From 2-bromo-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide with cesium carbonate and 3-methoxy-piperidine. ES-MS *m/e* (%): 484 ($M+H^+$, 100).

Example 29

- 10 2-(4-Ethyl-3-oxo-piperazin-1-yl)-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

From 2-bromo-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide with cesium carbonate and 1-ethyl-piperazin-2-one. ES-MS *m/e* (%): 519 ($M+Na^+$, 28), 497 ($M+H^+$, 100).

- 15 Analogously to Example 24 there was obtained:

Example 30

N-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-(tetrahydro-pyran-4-yl)-isonicotinamide

- 20 From 2-bromo-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide with tri-*n*-butyl-(3,6-dihydro-2*H*-pyran-4-yl)-stannane, bis(triphenylphosphine)palladium(II) chloride, triphenylphosphine, lithium chloride and 2,6-di-*tert*-butyl-4-methylphenol in DMF. Then hydrogenation using palladium on charcoal in methanol and dichloromethane. ES-MS *m/e* (%): 477 ($M+Na^+$, 16), 455 ($M+H^+$, 100).

Analogously to Example 7 there were obtained:

25

Example 31

N-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-((1*S*,4*S*)-2-oxa-5-aza-bicyclo[2.2.1]hept-5-yl)-isonicotinamide

From 2-bromo-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide with cesium carbonate and (1*S*,4*S*)-(+)-2-aza-5-oxabicyclo[2.2.1]heptane hydrochloride. ES-MS *m/e* (%): 590 ($M+Na^+$, 17), 468 ($M+H^+$, 100).

Example 32

- 5 2-(3-hydroxy-piperidin-1-yl)-*N*-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

From 2-bromo-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide with cesium carbonate and 3-hydroxy-piperidine. ES-MS *m/e* (%): 470 ($M+H^+$, 100).

Example 33

- 10 2-(4-hydroxy-piperidin-1-yl)-*N*-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

From 2-bromo-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide with cesium carbonate and 4-hydroxy-piperidine. ES-MS *m/e* (%): 470 ($M+H^+$, 100).

Example 34

- 15 6-Ethoxy-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-nicotinamide

a) 6-Chloro-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-nicotinamide

- To a stirred solution of 1.89 g (7.54 mmol) 6-chloro-nicotinic acid in 20 ml THF were added 2.87 g (7.54 mmol) HATU and 1.28 ml (7.54 mmol) *N*-ethyl-diisopropylamine and stirring continued at room temperature for 30 minutes. A solution of 2.00 g (7.54 mmol) 20 4-methoxy-7-morpholin-4-yl-benzothiazol-2-ylamine in 20 ml dioxane and 4 ml DMF was then added and stirring continued at room temperature for 16 h. The reaction mixture was then poured into 350 ml water and the mixture stirred for 30 min. The resulting crystals were collected by filtration, washed with methanol and then with ether, and dried *in vacuo* to afford 3.03 g (99%) 6-chloro-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-
25 nicotinamide as a yellow crystalline solid. ES-MS *m/e* (%): 429 ($M\{^{37}Cl\}+Na^+$, 15), 427 ($M\{^{35}Cl\}+Na^+$, 38), 407 ($M\{^{37}Cl\}+H^+$, 40), 405 ($M\{^{35}Cl\}+H^+$, 100).

b) 6-Ethoxy-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-nicotinamide

- To a stirred solution of 0.24 ml (4.94 mmol) ethanol in 5 ml dioxane at room temperature was added 270 mg (6.18 mmol) sodium hydride (55% dispersion in mineral oil) and the
30 mixture heated at 50 °C for 30 min. 500 mg (1.23 mmol) 6-chloro-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-nicotinamide was then added and the mixture heated

at 80 °C for 16 h. The reaction mixture was then cooled to room temperature and poured onto water. The mixture was extracted three times with dichloromethane, and the combined organic phases were dried over sodium sulfate and concentrated *in vacuo*. Flash chromatography (1/99 methanol/dichloromethane) followed by trituration in ether
5 afforded 270 mg (53%) 6-ethoxy-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-nicotinamide as a white crystalline solid. ES-MS *m/e* (%): 437 ($M+Na^+$, 26), 415 ($M+H^+$, 100).

In an analogous manner there was obtained:

Example 35

10 6-Methoxy-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-nicotinamide

From 6-chloro-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-nicotinamide with sodium hydride and methanol in dioxane and DMF. ES-MS *m/e* (%): 423 ($M+Na^+$, 15), 401 ($M+H^+$, 100).

Example 36

15 6-(4-Acetyl-piperazin-1-yl)-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-nicotinamide

A stirred suspension of 200 mg (0.49 mmol) 6-chloro-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-nicotinamide, 2.53 g (19.8 mmol) 1-acetylpiperazine and 290mg (0.89 mmol) cesium carbonate in 4 ml NMP in a thick-walled glass pressure tube fitted with a
20 teflon cap was heated at 120 °C for 24 h. The reaction mixture was then cooled to room temperature and poured onto water. The mixture was extracted three times with dichloromethane, and the combined organic phases were washed with saturated brine, dried over sodium sulfate, and concentrated *in vacuo*. Flash chromatography (0/99-4/96 methanol/dichlormoethane) followed by trituration in ether afforded 77 mg (31%) 6-(4-
25 acetyl-piperazin-1-yl)-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-nicotinamide as a white crystalline solid. ES-MS *m/e* (%): 519 ($M+Na^+$, 26), 417 ($M+H^+$, 100).

Analogously to Example 34 there was obtained:

Example 37

6-(2-Methoxy-ethoxy)-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-nicotinamide

From 6-chloro-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-nicotinamide with sodium hydride and 2-methoxyethanol in dioxane and DMF. ES-MS *m/e* (%): 467 ($M+Na^+$, 24), 445 ($M+H^+$, 100).

Analogously to Example 36 there were obtained:

5

Example 38

N-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-6-(4-methyl-piperazin-1-yl)-nicotinamide

From 6-chloro-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-nicotinamide with cesium carbonate and 1-methyl-piperazine in NMP. ES-MS *m/e* (%): 469 ($M+H^+$, 100).

10

Example 39

6-[(2*R*,6*S*)-2,6-Dimethyl-morpholin-4-yl]-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-nicotinamide

From 6-chloro-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-nicotinamide with cesium carbonate and *cis*-2,6-dimethyl-morpholine in NMP. ES-MS *m/e* (%): 506 ($M+Na^+$, 31), 484 ($M+H^+$, 100).

15

Example 40

N-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-6-[(pyridin-2-ylmethyl)-amino]-nicotinamide

From 6-chloro-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-nicotinamide with cesium carbonate and 2-picolyamine. ES-MS *m/e* (%): 499 ($M+Na^+$, 19), 477 ($M+H^+$, 100).

20

Example 41

6-(2-Methoxy-ethylamino)-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-nicotinamide

From 6-chloro-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-nicotinamide with cesium carbonate and 2-methoxyethylamine. ES-MS *m/e* (%): 444 ($M+H^+$, 100).

25

Analogously to Example 34 there were obtained:

Example 42

N-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-6-propoxy-nicotinamide

From 6-chloro-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-nicotinamide with sodium hydride and propanol in dioxane and DMF. ES-MS *m/e* (%): 429 ($M+H^+$, 100).

5

Example 43

6-Butoxy-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-nicotinamide

From 6-chloro-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-nicotinamide with sodium hydride and butanol in dioxane and DMF. ES-MS *m/e* (%): 465 ($M+Na^+$, 40), 443 ($M+H^+$, 100).

10

Example 44

6-Isopropoxy-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-nicotinamide

From 6-chloro-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-nicotinamide with sodium hydride and isopropanol in dioxane and DMF. ES-MS *m/e* (%): 451 ($M+Na^+$, 20), 429 ($M+H^+$, 100).

15

Example 45

6-Cyclohexyloxy-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-nicotinamide

From 6-chloro-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-nicotinamide with sodium hydride and cyclohexanol in dioxane and DMF. ES-MS *m/e* (%): 491 ($M+Na^+$, 24), 469 ($M+H^+$, 100).

20

Example 46

2-[[[2-Methoxy-ethyl)-methyl-amino]-methyl]-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

2-Chloromethyl-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide (240 mg, 0.55 mmol) is dissolved in *N*-(2-methoxyethyl)-methylamine (1.0 g, 12 mmol) and the mixture heated to 60 °C for 1 h. The volatile components are removed in vacuo and the residue chromatographed over SiO_2 eluting with dichloromethane/methanol 19/1. The title compound was obtained as yellow crystals (170 mg, 71 % yield). MS: *m/e*=472($M+H^+$).

Following the general method of example 46 the compounds of examples 47 - 62 were prepared.

Example 47

2-[(2-Methoxy-ethylamino)-methyl]-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

Using 2-methoxy-ethylamine the title compound was prepared as yellow crystals (68 % yield). MS: m/e=458 (M+H⁺).

Example 48

2-[[Ethyl-(2-methoxy-ethyl)-amino]-methyl]-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

Using N-ethyl-(2-methoxy-ethyl)-amine the title compound was prepared as off-white solid (76 % yield). MS: m/e=486 (M+H⁺).

Example 49

2-[[[(2-Ethoxy-ethyl)-ethyl-amino]-methyl]-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

Using N-(2-ethoxy-ethyl)-ethyl-amine the title compound was prepared as brown solid (67 % yield). MS: m/e=500 (M+H⁺).

Example 50

2-[(2-Ethoxy-ethylamino)-methyl]-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

Using 2-ethoxy-ethylamine the title compound was prepared as yellow solid (44 % yield). MS: m/e=472 (M+H⁺).

Example 51

2-[(Butyl-methyl-amino)-methyl]-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

Using N-butyl-methylamine the title compound was prepared as yellow solid (70 % yield). MS: m/e=470 (M+H⁺).

Example 52

2-Butylaminomethyl-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

Using butylamine the title compound was prepared as yellow solid (58 % yield). MS:

5 m/e=456 (M+H⁺).

Example 53

2-Diethylaminomethyl-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

Using diethylamine the title compound was prepared as light yellow solid (55 % yield).

10 MS: m/e=456 (M+H⁺).

Example 54

N-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-pyrrolidin-1-ylmethyl-isonicotinamide

Using pyrrolidine the title compound was prepared as yellow crystals (63 % yield). MS:

15 m/e=454(M+H⁺).

Example 55

N-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-piperidin-1-ylmethyl-isonicotinamide

Using piperidine the title compound was prepared as off-white solid (56 % yield). MS:

20 m/e=468 (M+H⁺).

Example 56

N-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-morpholin-4-ylmethyl-isonicotinamide

Using morpholine the title compound was prepared as light brown solid (76 % yield). MS:

25 m/e=470 (M+H⁺).

Example 57

N-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-(4-methoxy-piperidin-1-ylmethyl)-isonicotinamide

Using 4-methoxy-piperidine the title compound was prepared as light brown solid (99 % yield). MS: $m/e=498$ ($M+H^+$).

Example 58

N-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-methylaminomethyl-
5 isonicotinamide

Using methylamine the title compound was prepared as yellow crystals (30 % yield). MS: $m/e=414$ ($M+H^+$).

Example 59

2-Ethylaminomethyl-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-
10 isonicotinamide

Using ethylamine the title compound was prepared as yellow crystals (70 % yield). MS: $m/e=428$ ($M+H^+$).

Example 60

2-[(Cyclopropylmethyl-amino)-methyl]-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-
15 2-yl)-isonicotinamide

Using C-cyclopropyl-methylamine the title compound was prepared as yellow crystals (70 % yield). MS: $m/e=454$ ($M+H^+$).

Example 61

2-Azetidin-1-yl-methyl-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-
20 isonicotinamide

Using azetidine the title compound was prepared as yellow crystals (24 % yield). MS: $m/e=440$ ($M+H^+$).

Example 62

4-[[4-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl-carbamoyl)-pyridin-2-yl-methyl]-
25 amino]-butyric acid *tert*-butyl ester

Using 4-amino-butyric acid *tert*-butyl ester in 10 parts tetrahydrofurane the title compound was prepared as light brown solid (43 % yield). MS: $m/e=542$ ($M+H^+$).

Example 63

4-[[4-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl-carbamoyl)-pyridin-2-yl-methyl]-amino]-butyric acid

Treatment of 4-[[4-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-carbamoyl)-pyridin-2-yl-methyl]-amino]-butyric acid tert-butyl ester (214 mg, 0.40 mmol) with trifluoroacetic acid (15.0 ml, 13 mmol) yields the title compound in >95 % yield as light brown solid. MS: m/e=486 (M+H⁺).

Example 64

N-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-(2-oxo-pyrrolidin-1-yl-methyl)-isonicotinamide

To 2-pyrrolidinone (2.0 ml, 26 mmol) are added sodium hydride (45 mg, 1.1 mmol, 60% in mineral oil) followed after 15 min. by 2-chloromethyl-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide (210 mg, 0.50 mmol) and the remaining mixture is stirred for 3 h at 80°C. The mixture is then treated with water (15 ml) and evaporated to dryness. Flash chromatography (SiO₂, eluent: dichloromethane/methanol 19:1) and subsequent recrystallization from dichloromethane/ethanol afforded the title compound as yellow crystals (129 mg, 55 % yield). MS: m/e=468 (M+H⁺).

Example 65

[4-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl-carbamoyl)-pyridin-2-ylmethyl]-methyl-carbamic acid methyl ester

A solution of N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-methylaminomethyl-isonicotinamide (180 mg, 0.44 mmol) in tetrahydrofuran (15 ml) is subsequently treated with pyridine (52 µl, 0.65 mmol) and methyl chloroformate (43 µl, 0.57 mmol) and stirred at ambient temperature for 15 h. Additional pyridine (25 µl, 0.31 mmol) and methylchloroformate (20 µl, 0.26 mmol) are added and the mixture stirred for another hour. Saturated sodium hydrogen carbonate (15 ml) is added and the mixture extracted four times with ethyl acetate. The combined organic phases are dried with magnesium sulfate and evaporated to dryness. Flash chromatography (SiO₂, eluent: dichloromethane/methanol 19:1) afforded the title compound as yellow crystals (115 mg, 56 % yield). MS: m/e=472 (M+H⁺).

Example 66

2-(2-Methoxy-ethoxymethyl)-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

2-Methoxyethanol (2.6 ml, 48 mmol) is treated at 0 °C with sodium hydride (38 mg, 0.95 mmol, 60 % in mineral oil) and the remaining solution allowed to warm to ambient temperature over 1 h. *N*-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-methylaminomethyl-isonicotinamide (200 mg, 0.48 mmol, dissolved in tetrahydrofuran (2.0 ml), is added and the mixture stirred at 80 °C for 15 h. The mixture is then evaporated to dryness, treated with saturated sodium carbonate (20 ml) and extracted four times with each 20 ml dichloromethane. The combined organic phases are dried and evaporated. Flash chromatography (SiO₂, eluent: dichloromethane/methanol 20:0 to 19:1) afforded the title compound as light yellow crystals (104 mg, 48 % yield). MS: *m/e*=459 (M+H⁺).

Example 67

2-Methoxymethyl-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

N-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-methylaminomethyl-isonicotinamide (200 mg, 0.48 mmol, dissolved in tetrahydrofuran (5.0 ml), is treated with sodium methoxide (81 mg, 1.4 mmol) at 0°C and the mixture heated to 50°C for 15 h. The mixture is quenched with saturated sodium carbonate (4.0 ml), extracted four times with each 15 ml dichloromethane and the combined organic phases dried and evaporated. Flash chromatography (first SiO₂, eluent: dichloromethane/methanol 0 to 5% and second dichloromethane/ethyl acetate 30% to 60%) afforded the title compound as light yellow crystals (49 mg, 25 % yield). MS: *m/e*=415 (M+H⁺).

Preparation of intermediates for examples 46 to 67

Example 68 (intermediate)

2-Chloromethyl-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

To a solution of 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine (2.3 g, 8.7 mmol) in tetrahydrofuran (80 ml) is added *N*-ethyl-diisopropylamine (6.0 ml, 35 mmol) and the solution cooled to 0°C. 2-chloromethyl-isonicotinoyl chloride (2.4 g, 10.5 mmol), dissolved in tetrahydrofuran (50 ml), is added over 15 minutes and the mixture heated to 70°C for 1h. After evaporation of the volatile components, the residue was dissolved in ethyl acetate and water, filtered and the residue combined with the dried and evaporated organic phase. Recrystallization from dichloromethane/ethyl acetate afforded the title compound as light brown solid (2.9 g, 81 % yield). MS: *m/e*=420(M+H⁺).

Example 69

(2-Chloromethyl-isonicotinoyl chloride (intermediate))

- Hydrolysis of 2-chloromethyl-isonicotinic acid methyl ester (derived as described by
5 Scopes et al., *J. Med. Chem.* 1992, 35, 492) with LiOH in MeOH and water and subsequent
acid chloride formation with oxalyl chloride/dimethylformamide in dichloromethane gave
the title compound as light brown oil in about 80% yield, which was used without further
purification.

Example 70

- 10 *N*-(4-Methoxy-7-piperidin-1-yl-benzothiazol-2-yl)-2-pyrrolidin-1-yl-methyl-
isonicotinamide

Using 2-chloromethyl-*N*-(4-methoxy-7-piperidin-1-yl-benzothiazol-2-yl)-isonicotinamide
and pyrrolidine the title compound was prepared as described for example 46 as light yellow
crystals (67 % yield). MS: $m/e=452$ ($M+H^+$).

Example 71

15

N-(4-Methoxy-7-piperidin-1-yl-benzothiazol-2-yl)-2-morpholin-4-yl-methyl-
isonicotinamide

- Using 2-chloromethyl-*N*-(4-methoxy-7-piperidin-1-yl-benzothiazol-2-yl)-isonicotinamide
and morpholine the title compound was prepared as described for example 1 as light yellow
20 crystals (54 % yield). MS: $m/e=468$ ($M+H^+$).

Preparation of intermediates for examples 70 and 71.

Example 72

2-Chloromethyl-*N*-(4-methoxy-7-piperidin-1-yl-benzothiazol-2-yl)-isonicotinamide
(intermediate)

- 25 Using 4-methoxy-7-piperidin-1-yl-benzothiazol-2-yl-amine the title compound was
prepared as described for 2-chloromethyl-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-
2-yl)-isonicotinamide as yellow crystals (70 % yield). MS: $m/e=417$ ($M+H^+$).

Example 73

- 2-(1,1-Dioxo-1 λ 6-thiomorpholin-4-yl)-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-
30 yl)-isonicotinamide

a) N-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-thiomorpholin-4-yl-isonicotinamide

A stirred suspension of 500 mg (1.11 mmol) 2-bromo-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide, 1.15 g (11.1 mmol) thiomorpholine and 725 mg (2.23 mmol) cesium carbonate in a thick-walled glass pressure tube fitted with a teflon cap was heated at 140 °C for 48 h. The reaction mixture was then cooled to room temperature and poured onto water. The mixture was extracted three times with ethyl acetate, and the combined organic phases were washed with saturated brine, dried over sodium sulfate, and concentrated *in vacuo*. Flash chromatography (1/99 methanol/dichloromethane) followed by trituration in ether/ethyl acetate/hexane afforded 290 mg (55 %) N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-thiomorpholin-4-yl-isonicotinamide as an off-white crystalline solid. ES-MS m/e (%): 472 (M+H⁺, 100).

b) 2-(1,1-Dioxo-1,6-thiomorpholin-4-yl)-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

To a stirred solution of 500 mg (1.06 mmol) N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-thiomorpholin-4-yl-isonicotinamide in 5 ml methanol and 5 ml dichloromethane at room temperature was added 652 mg (1.06 mmol) oxone and stirring was continued for 60 h. The reaction was then quenched by careful addition of 5 ml saturated aqueous sodium hydrogensulfite solution and the pH of the resulting mixture was then adjusted to pH by addition of aqueous sodium bicarbonate solution. The mixture was extracted three times with dichloromethane and the combined organic phases were dried over sodium sulfate and concentrated *in vacuo*. Flash chromatography (0.5/99.5 methanol/dichloromethane) followed by trituration in ether afforded 90 mg (17%) 2-(1,1-Dioxo-1,6-thiomorpholin-4-yl)-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide as a yellow crystalline solid. ES-MS m/e (%): 504 (M+H⁺, 100).

Analogously to Example 7 there were obtained:

Example 74

2-(3-Hydroxy-azetidin-1-yl)-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

From 2-bromo-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide with cesium carbonate and azetidin-3-ol in NMP. ES-MS m/e (%): 442 (M+H⁺, 100).

Example 75

2-(3-Methoxy-azetidin-1-yl)-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

- From 2-bromo-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide with
5 cesium carbonate and 3-methoxy-azetidine hydrochloride in NMP. ES-MS m/e (%): 456
(M+H⁺, 100).

Example 76

2-(3-Ethoxy-azetidin-1-yl)-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

- 10 From 2-bromo-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide with
cesium carbonate and 3-ethoxy-azetidine hydrochloride in NMP. ES-MS m/e (%): 470
(M+H⁺, 100).

Analogously to Example 1 there were obtained:

Example 77

- 15 2-Isopropoxy-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

From 2-bromo-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide with
sodium hydride and isopropanol in dioxane and DMF. ES-MS m/e (%): 429 (M+H⁺, 100).

Example 78

2-Cyclohexyloxy-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

- 20 From 2-bromo-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide with
sodium hydride and cyclohexanol in dioxane and DMF. ES-MS m/e (%): 469 (M+H⁺,
100).

Analogously to Example 7 there was obtained:

Example 79

- 25 2-Cyclohexylamino-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

From 2-bromo-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide with
cesium carbonate and cyclohexylamine in NMP. ES-MS m/e (%): 468 (M+H⁺, 100).

Analogously to Example 1 there were obtained:

Example 80

N-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-methylsulfanyl-isonicotinamide

From 2-bromo-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide with
5 sodium methanethiolate in dioxane and DMF. ES-MS *m/e* (%): 417 ($M+H^+$, 100).

Example 81

2-Ethylsulfanyl-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

From 2-bromo-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide with
sodium ethanethiolate in dioxane and DMF. ES-MS *m/e* (%): 431 ($M+H^+$, 100).

10

Example 82

2-Butylsulfanyl-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

From 2-bromo-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide with
sodium hydride and butanethiol in dioxane and DMF. ES-MS *m/e* (%): 459 ($M+H^+$, 100).

Analogously to Example 7 there was obtained:

15

Example 83

2-Benzylamino-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

From 2-bromo-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide with
cesium carbonate and benzylamine. ES-MS *m/e* (%): 476 ($M+H^+$, 100).

Analogously to Example 1 there were obtained:

20

Example 84

2-Isobutoxy-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

From 2-bromo-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide with
sodium hydride and 2-methyl-propanol in dioxane and DMF. ES-MS *m/e* (%): 443
($M+H^+$, 100).

25

Example 85

2-Cyclopentyloxy-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

From 2-bromo-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide with sodium hydride and cyclopentanol in dioxane and DMF. ES-MS *m/e* (%): 455 ($M+H^+$, 100).

Example 86

- 5 2-(2-Dimethylamino-ethoxy)-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

From 2-bromo-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide with sodium hydride and 2-dimethylaminoethanol in dioxane and DMF. ES-MS *m/e* (%): 458 ($M+H^+$, 100).

10

Example 87

N-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-(2-morpholin-4-yl-ethoxy)-isonicotinamide

- From 2-bromo-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide with sodium hydride and *N*-(2-hydroxyethyl)morpholine in dioxane and DMF. ES-MS *m/e* (%) 15 (%): 500 ($M+H^+$, 100).

Analogously to Example 7 there were obtained:

Example 88

2-(2-Dimethylamino-ethylamino)-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

- 20 From 2-bromo-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide with cesium carbonate and 2-dimethylaminoethylamine. ES-MS *m/e* (%): 457 ($M+H^+$, 100).

Example 89

2-Cyclopentylamino-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

- 25 From 2-bromo-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide with cesium carbonate and cyclopentylamine. ES-MS *m/e* (%): 454 ($M+H^+$, 100).

Example 90

2-Cyclobutylamino-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

From 2-bromo-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide with cesium carbonate and cyclobutylamine. ES-MS *m/e* (%): 440 ($M+H^+$, 100).

Analogously to Example 36 there was obtained:

Example 91

- 5 6-[Ethyl-(2-methoxy-ethyl)-amino]-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-nicotinamide

From 6-chloro-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-nicotinamide with cesium carbonate and *N*-(2-methoxyethyl)ethylamine. ES-MS *m/e* (%): 472 ($M+H^+$, 100).

Analogously to Example 1 there was obtained:

10

Example 92

2-(2-Acetyl-amino-ethoxy)-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

From 2-bromo-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide with sodium hydride and *N*-acetyethanolamine in dioxane. ES-MS *m/e* (%): 472 ($M+H^+$, 100).

- 15 Analogously to Example 7 there were obtained:

Example 93

N-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-propylamino-isonicotinamide

From 2-bromo-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide with cesium carbonate and propylamine. ES-MS *m/e* (%): 428 ($M+H^+$, 100).

20

Example 94

N-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-(methyl-propyl-amino)-isonicotinamide

From 2-bromo-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide with cesium carbonate and *N*-methyl-*N*-propylamine in DMF. ES-MS *m/e* (%): 442 ($M+H^+$,

25 100).

Example 95

2-(Cyclohexyl-methyl-amino)-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

From 2-bromo-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide with
5 cesium carbonate and *N*-methylcyclohexylamine. ES-MS *m/e* (%): 482 ($M+H^+$, 100).

Example 96

2-(Benzyl-methyl-amino)-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

From 2-bromo-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide with
10 cesium carbonate and *N*-methylbenzylamine. ES-MS *m/e* (%): 490 ($M+H^+$, 100).

Example 97

N-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-(methyl-phenethyl-amino)-isonicotinamide

From 2-bromo-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide with
15 cesium carbonate and *N*-methyl-2-phenylethylamine. ES-MS *m/e* (%): 504 ($M+H^+$, 100).

Example 98

N-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-phenethylamino-isonicotinamide

From 2-bromo-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide with
cesium carbonate and phenylethylamine. ES-MS *m/e* (%): 490 ($M+H^+$, 100).

20

Example 99

2-[(2-Dimethylamino-ethyl)-methyl-amino]-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

From 2-bromo-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide with
cesium carbonate and *N,N,N'*-trimethylethylenediamine. ES-MS *m/e* (%): 471 ($M+H^+$,
25 100).

Example 100

N-(4-Methoxy-7-piperidin-1-yl-benzothiazol-2-yl)-2-(4-methyl-piperazin-1-yl)-isonicotinamide

From 2-bromo-*N*-(4-methoxy-7-piperidin-1-yl-benzothiazol-2-yl)-isonicotinamide with cesium carbonate and *N*-methylpiperazine. ES-MS *m/e* (%): 467 ($M+H^+$, 100).

Analogously to Example 1 there was obtained:

Example 101

5 2-Methoxy-*N*-(4-methoxy-7-phenyl-benzothiazol-2-yl)-isonicotinamide

From 2-bromo-*N*-(4-methoxy-7-phenyl-benzothiazol-2-yl)-isonicotinamide with sodium hydride and methanol in dioxane. ES-MS *m/e* (%): 392 ($M+H^+$, 100).

The following examples were made from intermediate 68(2-chloromethyl-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide) in the manner for example 46:

Example 102

2-(4-Hydroxy-piperidin-1-yl-methyl)-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

Using 4-hydroxy-piperidine the title compound was prepared as yellow crystals (68 % yield), mp 125°C. MS: *m/e*=484 ($M+H^+$).

Example 103

2-Ethylsulfanylmethyl-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

Using ethanethiol and *N*-ethyl-diisopropylamine (1.1.eq) and sodium methanolate (1 eq), the title compound was prepared as light brown crystals (41 % yield), mp 158-159°C. MS: *m/e*=445 ($M+H^+$).

Example 104

2-[[[(2-Ethoxy-ethyl)-methyl-amino]-methyl]-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

25 Using *N*-(2-ethoxy)-methylethylamine the title compound was prepared as yellow crystals (41 % yield), mp 159-160°C. MS: *m/e*=486 ($M+H^+$).

Example 105

(S)-2-(2-Methoxymethyl-pyrrolidin-1-ylmethyl)-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

Using (S)-2-methoxymethylpyrrolidine the title compound was prepared as yellow solid
5 (45 % yield), mp 110-113 °C. MS: m/e=498 (M+H⁺).

Example 106

(S)-2-(3-Methoxymethyl-pyrrolidin-1-ylmethyl)-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

Using (S)-3-methoxymethylpyrrolidine the title compound was prepared as light-yellow
10 solid (30 % yield), mp 93-96 °C. MS: m/e=498 (M+H⁺).

Example 107

N-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-(2-methyl-imidazol-1-ylmethyl)-isonicotinamide

Using 2-methyl-imidazole and dioxane the title compound was prepared as light-brown
15 solid (87 % yield), mp 264-265 °C. MS: m/e=465 (M+H⁺).

Example 108

2-[(Acetyl-methyl-amino)-methyl]-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

N-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-methylaminomethyl-
20 isonicotinamide (207 mg, 0.5 mmol) is dissolved in dichloromethane (10 ml) and treated with pyridine (0.07 ml, 0.85 mmol) and acetyl chloride (0.05 ml, 0.7 mmol) and stirred for 16 h at ambient temperature. Saturated aqueous sodium hydrogen carbonate (10 ml) is added, the layers are separated and the aqueous phase extracted twice with each 10 ml dichloromethane. The combined organic phases are dried with magnesium sulfate and
25 evaporated. Recrystallization from ethyl acetate afforded the title compound as light-yellow solid (80 % yield), mp 228-230°C. MS: m/e=456 (M+H⁺).

Following the method of example 108 the compound of 109 was prepared.


Example 109

2-[(Methoxyacetyl-methyl-amino)-methyl]-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide
30

Using methoxyacetyl chloride the title compound was prepared as yellow solid (73 % yield), mp 210°C. MS: m/e=486 ($M+H^+$).

Claims

1. Compounds of the general formula



wherein

R^1 is phenyl, piperidin-1-yl or morpholinyl;

A is -O- and

R is $-(CH_2)_n-N(R'')-C(O)$ -lower alkyl, $-(CH_2)_n-O$ -lower alkyl,
 10 $-(CH_2)_n-O-(CH_2)_n-O$ -lower alkyl, lower alkyl, $-(CH_2)_n$ -morpholinyl,
 $-(CH_2)_n$ -phenyl, $-(CH_2)_n-N(R'')_2$, $-(CH_2)_n$ -pyridinyl, $-(CH_2)_n-CF_3$,
 $-(CH_2)_n$ -2-oxo-pyrrolidinyl or C_{4-6} -cycloalkyl;
 R'' is independently from each other hydrogen or lower alkyl and
 n is 1 or 2; or

15 A is $-N(R')$ - and

R is lower alkyl, C_{4-6} -cycloalkyl, $-(CH_2)_n-O$ -lower alkyl, $-(CH_2)_n$ -pyridinyl,
 $-(CH_2)_n$ -piperidinyl, $-(CH_2)_n$ -phenyl, $-(CH_2)_n-N(R'')-C(O)$ -lower alkyl,
 $-(CH_2)_n$ -morpholinyl, or $-(CH_2)_n-N(R'')_2$;
 R' and R'' are independently from each other hydrogen or lower alkyl and
 20 n is 1 or 2; or

A is $-CH_2$ - and

R is $-N(R'')-(CH_2)_m-O$ -lower alkyl, $-N(R'')_2$, -S-lower alkyl or is acetidinyl,
 pyrrolidinyl or piperidinyl, which are optionally substituted by hydroxy or lower
 alkoxy or is morpholinyl, $-N(R'')-(CH_2)_m-C_{4-6}$ -cycloalkyl,
 25 $-N(R'')-(CH_2)_m-C(O)O$ -lower alkyl, $-N(R'')-(CH_2)_m-C(O)OH$,
 -2 -oxo-pyrrolidinyl, $-N(R'')-C(O)O$ -lower alkyl, $-O(CH_2)_m-O$ -lower alkyl or alkoxy;
 R'' is independently from each other hydrogen or lower alkyl and
 m is 1, 2 or 3;

or

A is -S- and

R is lower alkyl;

or

5 A-R are together

-piperazinyl, substituted by lower alkyl, -C(O)-lower alkyl or an oxo group, or is piperidinyl, substituted by lower alkoxy or hydroxy, or is morpholinyl, substituted by lower alkyl, or is -C₄₋₆-cycloalkyl, -azetidin-1-yl, optionally substituted by hydroxy or lower alkoxy, thiomorpholine-1,1-dioxo, -tetrahydropyran or

10 2-oxa-5-aza-bicyclo[2.2.1]hept-5-yl;

and pharmaceutically acceptable acid addition salts thereof.

2. Compounds of formula IA in accordance with claim 1.

3. Compounds in accordance with claim 2, wherein R¹ is morpholinyl.

4. Compounds in accordance with claim 3, wherein A is -O-.

15 5. Compounds in accordance with claim 4, wherein R is cycloalkyl, -(CH₂)_n-NHC(O)CH₃, -(CH₂)_n-N(R'')₂, -(CH₂)_n-O-lower alkyl or lower alkyl.

6. Compounds in accordance with claim 5, which compounds are
2-(2-methoxy-ethoxy)-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-
isonicotinamide,

20 2-ethoxy-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide,
2-methoxy-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide,
2-isopropoxy-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide,
2-cyclohexyloxy-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide,
2-cyclopentyloxy-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide,
25 2-(2-dimethylamino-ethoxy)-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-
isonicotinamide or
2-(2-acetyl-amino-ethoxy)-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-
isonicotinamide.

7. Compounds in accordance with claim 4, wherein R is $-(CH_2)_n$ -pyridinyl, $-(CH_2)_n$ -morpholinyl or $-(CH_2)_n$ -2-oxo-pyrrolidinyl.

8. Compounds in accordance with claim 7, which compounds are
 2-benzyloxy-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide,
 5 N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-(pyridin-2-ylmethoxy)-
 isonicotinamide,
 N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-[2-(2-oxo-pyrrolidin-1-yl)-
 ethoxy]-isonicotinamide or
 N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-(2-morpholin-4-yl-ethoxy)-
 10 isonicotinamide.

9. Compounds in accordance with claim 3, wherein A is $-N(R')-$.

10. Compounds in accordance with claim 9, wherein R is $-(CH_2)_n$ -pyridinyl, $-(CH_2)_n$ -piperidinyl, $-(CH_2)_n$ -phenyl or $-(CH_2)_n$ -morpholidinyl.

11. Compounds in accordance with claim 10, which compounds are
 15 N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-[methyl-(2-pyridin-2-yl-ethyl)-
 amino]-isonicotinamide,
 N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-(2-pyridin-2-yl-ethylamino)-
 isonicotinamide,
 N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-[(pyridin-2-ylmethyl)-amino]-
 20 isonicotinamide,
 2-[ethyl-(2-pyridin-2-yl-ethyl)-amino]-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-
 yl)-isonicotinamide,
 N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-(2-morpholin-4-yl-ethylamino)-
 isonicotinamide,
 25 N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-[methyl-(2-piperidin-1-yl-ethyl)-
 amino]-isonicotinamide,
 N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-(2-piperidin-1-yl-ethylamino)-
 isonicotinamide,
 2-benzylamino-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide,
 30 2-(benzyl-methyl-amino)-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-
 isonicotinamide,
 N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-(methyl-phenethyl-amino)-
 isonicotinamide or
 N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-phenethylamino-isonicotinamide.

12. Compounds in accordance with claim 9, wherein R is lower alkyl, cycloalkyl, $-(CH_2)_n-N(R'')_2$, $-(CH_2)_n-O$ -lower alkyl or $-(CH_2)_n-NR''-C(O)$ -lower alkyl.

13. Compounds in accordance with claim 12, which compounds are

- 2-[(2-methoxy-ethyl)-methyl-amino]-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide,
 2-(2-methoxy-ethylamino)-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide,
 2-[ethyl-(2-methoxy-ethyl)-amino]-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide,
 2-(2-ethoxy-ethylamino)-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide,
 2-(2-acetyl-amino-ethylamino)-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide,
 2-cyclohexylamino-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide,
 2-cyclopentylamino-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide,
 2-cyclobutylamino-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide,
 2-(2-dimethylamino-ethylamino)-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide,
 N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-propylamino-isonicotinamide,
 N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-(methyl-propyl-amino)-isonicotinamide,
 2-(cyclohexyl-methyl-amino)-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide or
 2-[(2-dimethylamino-ethyl)-methyl-amino]-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide.

14. Compounds in accordance with claim 3, wherein A is $-CH_2-$.

15. Compounds in accordance with claim 14, wherein R is $-N(R'')-(CH_2)_m-O$ -lower alkyl, $-N(R'')_2$, $-N(R'')-(CH_2)_m$ -cycloalkyl, S-lower alkyl or $-N(R'')-(CH_2)_m-C(O)O$ -lower alkyl.

16. Compounds in accordance with claim 15, which compounds are

- 2-[(2-methoxy-ethylamino)-methyl]-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide,
 2-[(2-ethoxy-ethylamino)-methyl]-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide,

- 2-[(butyl-methyl-amino)-methyl]-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide,
 2-butylaminomethyl-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide,
 5 2-diethylaminomethyl-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide,
N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-methylaminomethyl-isonicotinamide,
 2-ethylaminomethyl-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-
 10 isonicotinamide,
 2-[(cyclopropylmethyl-amino)-methyl]-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide,
 4-[[4-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-carbamoyl)-pyridin-2-yl-methyl]-amino]-butyric acid tert-butyl ester,
 15 [4-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-carbamoyl)-pyridin-2-ylmethyl]-methyl-carbamic acid methyl ester,
 2-ethylsulfanylmethyl-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide,
 2-[[[(2-ethoxy-ethyl)-methyl-amino]-methyl]-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide,
 20 2-Ethylsulfanylmethyl-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide,
 2-[[[(2-Ethoxy-ethyl)-methyl-amino]-methyl]-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide
- 25 17. Compounds in accordance with claim 14, wherein R is pyrrolidinyl, -2-oxo-pyrrolidinyl, piperidinyl, which is optionally substituted by lower alkoxy or hydroxy, or is morpholinyl or alkoxy.
18. Compounds in accordance with claim 17, which compounds are
- N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-pyrrolidin-1-ylmethyl-
 30 isonicotinamide,
N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-(2-oxo-pyrrolidin-1-yl-methyl)-isonicotinamide,
N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-(4-methoxy-piperidin-1-ylmethyl)-isonicotinamide,
 35 *N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-piperidin-1-ylmethyl-isonicotinamide,
 2-(4-hydroxy-piperidin-1-ylmethyl)-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-

isonicotinamide,

N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-morpholin-4-ylmethyl-

isonicotinamide,

2-methoxymethyl-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide

5 or

2-(4-hydroxy-piperidin-1-yl-methyl)-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide.

19. Compounds in accordance with claim 3, wherein A is -S-.

20. Compounds in accordance with claim 19, which compounds are

10 *N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-methylsulfanyl-isonicotinamide or
2-ethylsulfanyl-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide.

21. Compounds in accordance with claim 3, wherein A – R are together -piperazinyl,
substituted by lower alkyl, -C(O)-lower alkyl or an oxo group, or is piperidinyl, substituted
by lower alkoxy or hydroxy, or is morpholinyl, substituted by lower alkyl, or is -cyclohexyl,
15 -azetidin-1-yl, which is optionally substituted by hydroxy or lower alkoxy, or is
-tetrahydropyran, or is 1,1-dioxo-thiomorpholinyl or 2-oxa-5-aza-bicyclo[2.2.1]hept-5-yl.

22. Compounds in accordance with claim 21, which compounds are

N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-(4-methyl-piperazin-1-yl)-
isonicotinamide,

20 2-(4-acetyl-piperazin-1-yl)-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-
isonicotinamide,

N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-(4-methyl-3-oxo-piperazin-1-yl)-
isonicotinamide,

25 2-(4-ethyl-3-oxo-piperazin-1-yl)-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-
isonicotinamide,

2-[(2*R*,6*S*)-2,6-dimethyl-morpholin-4-yl]-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-
2-yl)-isonicotinamide,

2-cyclohexyl-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide,

2-azetidin-1-yl-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide,

30 *N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-(4-methoxy-piperidin-1-yl)-
isonicotinamide,

N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-(3-methoxy-piperidin-1-yl)-
isonicotinamide,

2-(3-hydroxy-piperidin-1-yl)-*N*-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-

35 isonicotinamide,

N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-(tetrahydro-pyran-4-yl)-isonicotinamide,

N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-((1*S*,4*S*)-2-oxa-5-aza-bicyclo[2.2.1]hept-5-yl)-isonicotinamide,

5 2-(1,1-dioxo-11 6-thiomorpholin-4-yl)-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide,

2-(3-hydroxy-azetidin-1-yl)-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide,

2-(3-methoxy-azetidin-1-yl)-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-
10 isonicotinamide or

2-(3-ethoxy-azetidin-1-yl)-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide.

23. Compounds in accordance with claim 2, wherein R¹ is piperidinyl.

24. Compounds in accordance with claim 23, wherein A is -CH₂- and R is
15 pyrrolidinyl or morpholidinyl.

25. Compounds in accordance with claim 24, wherein the compounds are

N-(4-methoxy-7-piperidin-1-yl-benzothiazol-2-yl)-2-pyrrolidin-1-yl-methyl-isonicotinamide or

N-(4-methoxy-7-piperidin-1-yl-benzothiazol-2-yl)-2-morpholin-4-yl-methyl-
20 isonicotinamide.

26. Compounds of formula IB in accordance with claim 1.

27. Compounds in accordance with claim 26, wherein R¹ is morpholinyl.

28. Compounds in accordance with claim 27, wherein A is -O- and R is lower alkyl,
25 -(CH₂)₂-O-lower alkyl or cycloalkyl.

29. Compounds in accordance with claim 28, which compounds are

6-methoxy-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-nicotinamide,
30 6-isopropoxy-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-nicotinamide,
6-(2-methoxy-ethoxy)-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-nicotinamide
or
6-cyclohexyloxy-*N*-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-nicotinamide.

30. Compounds in accordance with claim 23, wherein A - R are together piperazinyl,
35 substituted by lower alkyl.


31. Compounds in accordance with claim 30, which compound is
N-(4-methoxy-7-piperidin-1-yl-benzothiazol-2-yl)-2-(4-methyl-piperazin-1-yl)-
 isonicotinamide.

32. Compounds in accordance with claim 2, wherein R¹ is phenyl, A is -O- and R is
 5 lower alkyl.


33. Compounds in accordance with claim 32, which compound is
 2-methoxy-*N*-(4-methoxy-7-phenyl-benzothiazol-2-yl)-isonicotinamide.

34. A process for preparing a compound of formula IA or IB as defined in claim 1,
 10 which processes comprise

a) reacting a compound of formula




(4A) or




(4B)

with a compound of formula




15 in the presence of a base

to a compound of formula



IA1 or




IB1


wherein R is -(CH₂)_n-N(R'')-C(O)-lower alkyl, -(CH₂)_n-O-lower alkyl,
 -(CH₂)_n-O-(CH₂)_n-O-lower alkyl, lower alkyl, -(CH₂)_n-morpholinyl,
 20 -(CH₂)_n-phenyl, -(CH₂)_n-N(R'')₂, -(CH₂)_n-pyridinyl, -(CH₂)_n-CF₃,
 -(CH₂)_n-2-oxo-pyrrolidinyl or C₄₋₆-cycloalkyl, Y is chloro or bromo, A is oxygen or sulfur,
 and n is 1 or 2;

- 70 -

b) reacting a compound of formula




(4A) or




(4B)


with a compound of formula



5 to a compound of formula




1A2 or




1B2

wherein R is lower alkyl, C₄₋₆-cycloalkyl, -(CH₂)_n-O-lower alkyl, -(CH₂)_n-pyridinyl, -(CH₂)_n-piperidinyl, -(CH₂)_n-phenyl, -(CH₂)_n-N(R'')-C(O)-lower alkyl, -(CH₂)_n-morpholinyl or -(CH₂)_n-N(R'')₂ or R and R' form together with the N atom the following groups: piperazinyl, optionally substituted by lower alkyl, C(O)-lower alkyl or an oxo group, piperidinyl, optionally substituted by lower alkoxy or hydroxy, morpholinyl, optionally substituted by lower alkyl, azetidin-1-yl, optionally substituted by hydroxy or lower alkoxy, or thiomorpholine-1,1-dioxo or 2-oxa-bicyclo[2.2.1]hept-5-yl, R' and R'' are independently from each other hydrogen or lower alkyl, Y is chloro or bromo and n is 1 or 2; or

c) reacting a compound of formula



4A1 or





4B1

- 71 -

with a compound of formula

H-R (9)



to a compound of formula

IA3-1_{or}

IB3-1

- 5 wherein R is $-N(R'')-(CH_2)_m-O$ -lower alkyl, $-N(R'')_2$, $-S$ -lower alkyl or is acetidinyl, pyrrolidinyl or piperidinyl, which are optionally substituted by hydroxy or lower alkoxy or is morpholinyl, $-N(R'')-(CH_2)_m-C_{4-6}$ -cycloalkyl, $N(R'')-(CH_2)_m-C(O)O$ -lower alkyl, $-N(R'')-(CH_2)_m-C(O)OH$, -2 -oxo-pyrrolidinyl, $-N(R'')-C(O)O$ -lower alkyl, $-O(CH_2)_m-O$ -lower alkyl or alkoxy,
- 10 R'' is independently from each other hydrogen or lower alkyl and m is 1, 2 or 3, or

d) reacting a compound of formula



4A1_{or}

4B1

with a compound of formula

H-O-R (5)

- 15 to give a compound of formula


IA3-2_{or}

IB3-2


wherein R is $-(CH_2)_m-O$ -lower alkyl or is lower alkyl and m is 1, 2 or 3, or

- 72 -

e) reacting a compound of formula




(4A) or




(4B)


with a compound of formula



5 to a compound of formula




IA4 or




IB4

wherein A'-R are together C₄₋₆-cycloalkenyl or dihydropyran and Y is bromo,

and then reacting a compound of formula IA4 or IB4 with hydrogen and a catalyst to give a compound of formula



IA5 or



IB5

10

wherein A-R are together C₄₋₆-cycloalkyl or tetrahydropyran,

and

if desired, converting the compounds obtained into pharmaceutically acceptable acid addition salts.

15

35. A compound according to any one of claims 1 to 33, whenever prepared by a process as claimed in claim 34 or by an equivalent method.

36. A medicament containing one or more compounds as claimed in any one of claims 1 to 33 and pharmaceutically acceptable excipients,

37. A medicament according to claim 36 for the treatment of diseases related to the adenosine receptor.

5 38. The use of a compound in any one of claims 1 to 33 for the treatment of diseases.

39. The use of a compound in any one of claims 1 to 33 for the manufacture of corresponding medicaments for the treatment of diseases related to the adenosine A_{2A} receptor.

40. The invention as hereinbefore described.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 02/12562

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/4439 C07D417/12 C07D417/14

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

WPI Data, PAJ, CHEM ABS Data, BEILSTEIN Data, EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 01 97786 A (HOFFMANN LA ROCHE) 27 December 2001 (2001-12-27) see example 79, page 10, lines 1819, page 14, lines 31-33 and general formula ---	1-5, 14, 26-28, 32, 34-40
A	EP 0 295 656 A (EISAI CO LTD) 21 December 1988 (1988-12-21) see definitions of R5 and R6 and R2 and example 51 --- -/--	1-40



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the International filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

12 February 2003

Date of mailing of the international search report

19/02/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3018

Authorized officer

Scruton-Evans, I

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 02/12562

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	BARALDI P G ET AL: "Design, synthesis, and biological evaluation of a second generation of pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidines as potent and selective A2A adenosine receptor antagonists" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 41, 1998, pages 2126-2133, XP002163351 ISSN: 0022-2623 the whole document	1-40
A	BARALDI P G ET AL: "COMPARATIVE MOLECULAR FIELD ANALYSIS (COMFA) OF A SERIES OF SELECTIVE ADENOSINE RECEPTOR A2A ANTAGONIST" DRUG DEVELOPMENT RESEARCH, NEW YORK, NY, US, vol. 46, no. 2, 1999, pages 126-133, XP008004853 ISSN: 0272-4391 the whole document	1-40

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 02/12562

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0197786	A	27-12-2001	AU 8181701 A WO 0197786 A2 US 2002045615 A1	02-01-2002 27-12-2001 18-04-2002
EP 0295656	A	21-12-1988	AT 82276 T AU 610186 B2 AU 1769988 A CA 1322369 A1 CN 1030757 A DD 282686 A5 DE 3875809 D1 DE 3875809 T2 DK 328888 A EP 0295656 A1 ES 2045017 T3 FI 882692 A ,B, GR 3006207 T3 HU 47554 A2 JP 1079162 A JP 2793195 B2 KR 9105709 B1 NO 882627 A ,B, NZ 224946 A PH 26553 A PT 87747 A ,B SU 1731051 A3 US 4929623 A ZA 8804277 A	15-11-1992 16-05-1991 22-12-1988 21-09-1993 01-02-1989 19-09-1990 17-12-1992 15-04-1993 18-12-1988 21-12-1988 16-01-1994 18-12-1988 21-06-1993 28-03-1989 24-03-1989 03-09-1998 02-08-1991 19-12-1988 26-07-1990 19-08-1992 01-07-1988 30-04-1992 29-05-1990 29-03-1989